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ABSTRACT
Many human disorders are associated with the malfunction of smooth muscle
tissue, or are related to the capabilities of its proper function—asthma, glaucoma, renal
inefficiency, hypertension, and cardiovascular disease. Dysfunctional proteins are
frequently implicated as the source of such disorders. As the second highest cause of
death in the United States, the epidemic of cardiovascular disease makes the study of
smooth muscle of utmost concern.
The capabilities of proteomics and mass spectrometry allow the entire proteome
complement of a cell or tissue type to be analyzed at once. This investigation employs
such techniques in an effort to better understand the mechanisms of signal transduction
for the contraction of smooth muscle tissue. The differential phosphorylation of proteins
between resting and contracted tissue was targeted, specifically, because phosphorylation
is the primary means of communication and activity modification of proteins. Much of
what is known about the regulation of signal transduction in smooth muscle contraction is
conducted through the activation of myosin light chain kinase (MLCK) and/or myosin
light chain phosphatase (MLCP).
Protocols of analysis using phosphoproteomic techniques and MALDI-TOF MS
were developed for the purposes of this investigation. The localization of the more
abundant proteins actin, myosin heavy chain (MHC), and tropomyosin was determined
on a 2D gel. Tropomyosin was found to be phosphorylated in phorbol-contracted tissue,
indicating that this protein may play a larger role in contractile regulation than originally
thought. The function of such thin-filament associated proteins should be investigated
more thoroughly. A thorough understanding of contraction in normal tissue will provide
the base for which dysfunctions can be compared. Continued improvements in
methodology will aid the advancement of this research.
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INTRODUCTION

Smooth Muscle
Smooth muscle (SM) tissue consists of the involuntary muscles found in the lining of
most hollow organs, including blood vessels, and functions to produce and regulate tension and
mechanical processes. The primary function of SM is contraction—tension development and
maintenance. Generated force is used to regulate such processes as blood flow/circulation,
movement through the gastrointestinal (GI)/urogenital (UI) tracts, retinal function (light
reactions, pressure), and laboral uterine contractions (Abdel-Latif, 2001). SM tissue can be
classified into six different types: vascular, respiratory, urinary, reproductive, gastrointestinal,
and ocular.
Many disorders are associated with either the malfunction of SM tissue, or are related to
the capabilities of its proper function. These include cardiovascular disease, hypertension (high
blood pressure), glaucoma, asthma, renal inefficiency, restenosis, atherosclerosis, and cerebral
vasospasm. In particular, overconstriction, or blockage of blood vessels, can cause hypertension
and heart disease.
According to research conducted by the World Health Organization (WHO),
approximately 16.6 million people around the world die a year from cardiovascular-associated
disorders with approximately 600 million people at high risk for heart attack, stroke, and/or
cardiac failure (WHO, 2002). What’s more these numbers are growing (WHO 2002). To add to
the weight of this problem, the age of monitored patients is decreasing. The average age of
afflicted patients used to be in the 70s, but has grown to include those in their 30s or 40s
(Nurseweek, 2003).
An estimated $352 billion a year will be spent in America for the treatment and disability
coverage of heart disease. As the leading cause of death in many countries, including the United
States, risk factors include: hypertension, high cholesterol, obesity, diabetes, heredity, tobacco
use, poor diet, increasing age, physical inactivity, and excess alcohol intake (AHA, 2003).
Treatment and prevention of this epidemic begins with an understanding of normal SM
function—both its mechanical and biochemical properties. Devising how signaling pathways are
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altered during the state of disease would be the next step to develop treatments for a disorder.
For example, one of the primary treatments for patients enduring overconstriction of blood
vessels or airways is to treat them with a vasodilator, an agonist that signals SM tissue to relax,
such as nitroglycerine which produces nitric oxide (NO).
Smooth muscle can be characterized as either tonic or phasic (Somlyo 1968, 1990).
Phasic SM demonstrates activation of contraction via the production of action potentials, and
develops faster shortening and tension development (Somlyo 1968, 1993, 1994; Johansson
1980). Tonic SM exhibits graded polarization, or slower waves of Ca2+ influx (Fuglsang 1993;
Somlyo 1993; Prosser 1992).

Smooth Vs. Skeletal: Similarities
Composition
Both smooth and skeletal muscle have many of the same proteins related to contractile
activities and/or signal transduction, although they have different isoforms. (see appendix III for
protein info.) Such proteins include: actin, myosin, MgATPase, calmodulin (CaM), voltagedependent anion channels, and myosin light chain kinase (MLCK)—though the structure of this
protein in the two muscles is very different (Hartshorne 1987). Actin is made up of G-actin
monomers that compose the thin filaments to make F-actin. Myosin is a hexameric protein. The
six monomers that make up myosin consist of two heavy chains (MHC), two essential light chain
monomers (MLCessential) and two myosin regulatory light chains (MLC-20) (See Appendix IV).
Regulation of Contraction
Both types of muscle contractions are regulated by depolarization states of the plasma
membrane ( PM) and cytosolic concentrations of calcium ([Ca2+]), referred to as
electromechanical coupling. Electrical depolarization of the membrane from a resting potential
of -70 to -40 mV (depending on the cell type) to a more positive potential causes the opening of
voltage-gated calcium (Ca2+) channels in the plasma membrane (PM) and the sarcoplasmic
2

reticulum (SR) leading to increased levels of cytosolic Ca2+ (Somlyo 1989; Johansson 1980).
Contraction occurs with a change to a more positive membrane potential (depolarization),
relaxation occurs when the potential switches back to a more negative potential (repolarization),
(Filo 1965; Somlyo 1998).
Mechanism of Contraction
Both muscles use the same actomyosin molecular motor (MgATPase) to facilitate
mechanical contraction via the familiar, well-researched sliding filament mechanism. Briefly, a
phosphorylated myosin regulatory light chain (MLC-20) from myosin thick filaments enables the
MgATPase motorized myosin head to walk along the thin filaments of actin (F-actin), shortening
and contracting muscle fibers (Figures 1 and 2, below).

Figure 1: Illustration of the mechanism of the sliding filament model in a repeated 5 step operation. 1) Myosin
heads are bound to actin filaments at the myosin binding site. 2) ATP binds to the regulatory light chain of myosin
(MLC-20). The myosin head dissociates. 3) Hydrolysis of ATP causes a conformational change in the myosin head
into a “cocked” formation. 4) The myosin head binds the actin filament again. 5) ADP is released, and the myosin
head pulls the myosin filament forward in the “power stroke”.

3

Figure 2: Model of the sliding filament mechanism of contraction, in which activated MgATPase myosin heads
walk along actin filaments to shorten and contract fiber lengths.

These actomyosin interactions are called cross-bridges. Similarity in the behavior of forcevelocity relationships in response to changes in muscle length and tension development support
this theory of analogous contraction (Hibberd 1989; Somlyo 1988, Horiutu 1989; Arner 1987;
Fuglsang 1993).
Smooth Vs. Skeletal: Differences
Ultrastructure and Composition
Though the two types of muscle fibers share similar components and the same general
mechanism, they differ in their ultrastructural design, and consequently, many of their
mechanical properties. Skeletal muscle fibers are arranged in a striated organization of stacked
filaments in repeating units called sarcomeres. Smooth muscle fibers exist as ordered arrays of
crossed filaments (Figures 3 and 4, below). SM also has a greater ratio of actin to myosin, with a
much lower level of myosin than skeletal muscle. The abundances of actin and tropomyosin are
consistent with skeletal muscle. Actin filaments are attached to dense bodies containing αactinin, assumed to be analogous to the Z-discs in skeletal muscle.
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Figure 3: Illustration of the arrangement or skeletal muscle fibers—repeating units of the sarcomere.

Figure 4: Arrangement of smooth muscle fibers in ordered arrays of crossed filaments.

Mechanism of Contraction
The mechanism by which increasing [Ca2+] induces contraction in skeletal and smooth
muscle differs, as well. In skeletal muscle, Ca2+ binds to troponin C (TnC)—a regulatory protein
associated with actin through tropomyosin (Tm)—that causes a conformational change which
moves tropomyosin from blocking the actomyosin interaction (Ebashi 1991).

5

Figure 5: Illustration of the mechanism by which induces contraction in skeletal muscle. Troponin C
binds Ca2+ and causes a conformational change in Tropomyosin, which moves from inhibiting myosin from the
actomyosin binding site.

SM does not have troponin proteins. It has calponin and caldesmon associated with its
thin filaments. In SM, Ca2+ binds to Calmodulin (CaM), and this complex then binds myosin
light chain kinase (MLCK). The Ca-CaM-MLCK complex then phosphorylates MLC-20 at
serine 19, allowing contraction (Hartshorne 1987; Sweeney 1994). However, it has been
proposed that thin-filament-associated proteins in SM aid in regulation of contraction when
phosphorylated by a kinase (Adam 1992; Sobue 1991; Marsten 1991; Winder 1993).
Regulation of Contraction
The two types of muscle also differ in the stimulus and regulation of
contraction/relaxation. Skeletal muscle cell depolarization of the membrane is activated by
nerve impulses that release acetylcholine and induce subsequent depolarization. Smooth muscle
contraction is controlled not only by depolarization, but also by many signaling molecules and
cross-talking pathways, called pharmacochemical coupling. Table 1 lists some common agonists
6

of contraction and relaxation. Contraction may be regulated by calcium-independent
mechanisms, where constant [Ca2+] levels are associated with changes in the level of MLC-20
phosphorylation and/or tension. This phenomenon is called calcium
sensitization/desensitization, depending on whether the contractile response becomes more or
less sensitive to [Ca2+].

Agonists of Contraction
High Cytocolic Ca2+
High Extracelluar K+ (KCl)
Depolarization of membrane
STOCs
Angiotension
Norepenephrine
Catacholamines
Histamine
Triethanolamine (TEA)
Polycations
-spermin, neomycin, polylysine
Endothelin (ET)
Bradykinin
Phorbol esters
Prostaglandin F2 (PGF2)
Muscarine
Oxotremorin
Serotonin
5-hydroxytryptamine
Interleukin-1
Vasopressin
Thrombin
carbachol
Methylene blue
Superoxide
Oxytocin

Stimulants of Relaxation
Low cytosolic Ca2+
Hyerpolarization of membrane
STICs
Dantrolene
Kaurenoic acid
Adrenomedullin
Prostaglandin E2 (EP2)
Calcitonin gene-related peptide
β-Adrenergic receptor agonist
Inhibitors of CaM
-trifluoroperazine, mastoparan, W13
Elevators of cAMP/cGMP
Forskolin
Isoproterenol
Prazosin
Rnd1
Y-27632 (ROK inhibitor)
ERK inhibitors
Vasonatrin peptide
Some tyrosine kinase inhibitors
IBMX
NO
Atrial natriuretic peptide
ERF
EDHF (hyperpolarizing factor)

Table 1: Common agonists and inhibitors of contraction and relaxation in smooth muscle tissue.

Regulatory proteins demonstrate changes in function independent of cytosolic [Ca2+]. Such
regulation often occurs when contraction is stimulated by agonist-induced receptor activated
contraction in what is called pharamacomechanical coupling. Such sensitization/desensitization
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is manifested primarily in the regulation of MLC-20 phosphorylation, activity of MLCK, and/or
activity of myosin light chain phosphatase (MLCP), as will be discussed.
Mechanical Properties
The differences in structure are accompanied by unique mechanical properties of SM
tissue. For example, smooth muscle demonstrates maximum force generation at a specific given
length. Yet, it operates at a length far below this optimum. When SM is stretched beyond this
length, an increasing interference of passive force—that not generated by the active muscle—
causes stress relaxation and hysteresis, which poses as a problem for those trying to measure its
mechanical features, and is probably why SM does not operate in this range. Smooth muscle
also demonstrates much greater series elasticity, which is the length to which the tissue can be
stretched while maintaining its mechanical properties (Van Magstrigt 2002).
Smooth muscle tissue can demonstrate a sustained state of contraction, called tonic
contraction, as well as phasic contraction. Skeletal muscles operate only as rapid phasic
contractions (brief, intense contractions). However, skeletal muscle has a faster maximum
shortening velocity and MgATPase activity (Somlyo 1988; Horiutu 1989).
The work of Wright et al. at the Marshall University School of Medicine (MUSOM) has
demonstrated the ability of SM to generate more force per unit of cross-sectional area than
skeletal muscle (Wright, 2003). Smooth muscle also demonstrates an increased number of crossbridge attachments and is slow to redevelop force after quick release of tension (Somlyo 1967).
Yet, SM shows improved energy metabolism, with the ability to use less ATP to maintain force
(Hartshorne 1987; Siegman 1980; Rembold 1993).
Unique to SM is a phenomenon known as latch. There is no direct correlation between
the level of MLC-20 phosphorylation and force (Pfitzer 2001), and this is probably due to
maintenance of cross-bridge association without phosphorylation. This characteristic is known
as latch (Huxley 1957). Such differences in mechanical properties are undoubtedly accompanied
by differences in the biochemistry of involved proteins which perform and regulate contractility
functions.
SM Heterogeneity
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A striking lone aspect of SM tissue lies in its inherent heterogeneity. The same agonist
can elicit different responses in different types of SM tissue, or even in different segments of the
same vessel. The same pharamacochemical agent can cause contraction in one tissue, and
relaxation in another (Bulbring 1993). Agonists can be coupled to Ca2+-dependent or Ca2+independent contraction, and many agonists/relaxing agents are coupled to G-protein
receptors. The efficiency with which an agonist induces a response can also differ greatly
(Somlyo 1994).
Smooth Muscle Mechanics
The mechanical properties of SM are characterized by force/tension development of
tissue as a function of tissue length and time. Such properties are referred by measuring the
velocity of change in tension when tissue is shortened or stretched. Properties are investigated
from two perspectives 1) analysis of physiological muscle properties to generate normal forcevelocity curves, and 2) analysis of properties outside the physiological range, which demonstrate
series elasticity (Van Magstrigt 2002).
Two methods exist for producing force-velocity curves. One can either add load
(weights) to active muscle and record length changes, or apply shortening velocities to the
muscle to reach a given length, followed by recording of changes in force. However, activities
should be repeated to eliminate measurements of passive force (Van Mastrigt 1985). Factors that
affect mechanical properties include muscle size, number of cross-bridges, orientation of crossbridges to each other (series, parallel), and duration of exposure to stimuli (Van Mastrigt 2002).
The force-velocity relationship in SM fits the parabolic curve generated by the Hill
equation (Hill 1985), except when stretched, where the curve becomes more linear. Passive
force becomes a large influence on measurements starting from the point of optimal force
development and probably causes a large amount of this linearity (Uvelius 1977, 1979, 1980;
Moriya 1985; Stephens 1985; Van Koeveringe 1997). No apparent explanation exists for the
effects of stretching on shortening velocities, and conflicting supporting data is reflected in the
literature (Uvelius 1977; Malmqvist 1991; Minekus 2001; Van Mastrigt 1999).
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Signal Transduction Pathways
The SM cell is a complex structure with many points of regulation. Several signaling
pathways within the SM cell have been elucidated in the past 30 years. The following
subsections include diagrams of the complex pathways, which will be discussed briefly within
the text. Figure 6, below, defines the symbols used in the diagrams of signal transduction
pathways.

Figure 6: Legend defining the symbols used in the diagrams of signal transduction pathways in SM cells.

Ca2+ Influx
Calcium (Ca2+) influx occurs through Ca2+ channels in the plasma membrane (PM) and
the sarcoplasmic reticulum (SR). The rate of influx depends on the kinetic properties of the ion
channels (Kotlikoff 1999). Depolarization of the PM from resting potential to a more positive
potential—from -70 to -40 mV, depending on cell type— causes opening of voltage-gated ion
channels, and subsequent contraction. Repolarization of the cell membrane to a more negative
potential results in relaxation (Somlyo 1989; Johansson 1980).
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Ca2+ Flux in SM

Figure 7: Diagram illustrating the flux of calcium ions within the SM cell.

In the cytoplasm, calcium-binding buffer proteins bind the influx of excess Ca2+
(Kargacin 1994). It has now been proposed that the local distribution of buffers and contractileregulating proteins near the site of influx governs the nature and the extent of the response (Iino
1989). An action potential in phasic SM exceeds the buffering capacity of the cell and the signal
to contract is initiated (Bond 1984). The level of excess [Ca2+] depends on the extent of
depolarization and the concentration of surrounding buffers.
Voltage-gated ion channels are activated by depolarization, and are specific for calcium.
Ligand-gated ion channels are non selective and may function to activate voltage-dependent
channels (Somlyo 1991; Somlyo 1994). The properties of ion channels vary between smooth
muscle cell type, as well (Kuriyama 1992; McDonald 1994). To facilitate relaxation, most of the
11

Ca2+ is removed from the cytosol by the Ca2+-pump of the SR, though some is removed by the
Ca2+-ATPase pump and a Na+/ Ca2+ exchanger pump in the PM (Bond 1984; Carafoli 1993;
Juhaszova 1993; Aaronson 1981).
Recently, the potent effects of Ca2+ sparks on membrane potential have been studied
(Nelson 1995). These sparks are local, short-lived releases of Ca2+ through Ryanodine receptors
(RyaR)—at least ten (ZhuGe 2000)—in the SR, causing a high local [Ca2+]. The effect depends
on the local environment of the spark. The excess local Ca2+ can 1) activate IP3 receptors to
generate a larger “wave” of Ca2+ due to faster diffusion of IP3 (Jaggar 2000; Ganitkevich 2002),
or 2) activate Ca2+-activated potassium (K+) channels (BK channels), causing hyperpolarization
and relaxation—STOCs (spontaneous transient outward currents) (Bolton 1996), or 3) may
induce Ca2+-activated chloride (Cl-) ion channels and cause depolarization and contraction—
STICs (spontaneous transient inward currents) (ZhuGe 1998). Several messengers, in known
signaling pathways, cause increases or decreases in Ca2+ spark frequency (Porter 1998; Wellman
2001; Bonev 1997; Jaggar 2000).
Calcium Sensitization/Desensitization
As referred to before, calcium sensitization/desensitization is mediated mostly through
changes in the function of MLC-20, MLCK, MLCP, or even the actomyosin MgATPase itself.
The extent of MLC-20 phosphorylation depends on the relative activation/deactivation of
MLCK/MLCP, which are the main targets of regulatory proteins. However, changes in
contraction can occur without changes in MLC-20 phosphorylation. It has been suggested that
thin-filament-associated proteins—caldesmon, calponin—mediate cross-bridge attachments in
smooth muscle as they do in skeletal muscle, possibly when phosphorylated by mitogenactivated protein kinase (MAPK) (Arner 1999; Adam 1992; Sobue 1991; Marston 1991; Winder
1993). It has also been found that small heat shock proteins may directly inhibit the MgATPase,
when they are phosphorylated by PKA or PKG (Barany 1996; Beal 1997; Rembold 2000;
Brophy 1999).
Phosphorylation has also been shown to decline without loss of tension (Kamm 1985;
Fischer 1989; Sward 2000), and it has been suggested that MLC-20 is actually dephosphorylated
while cross-bridges are still intact or are slowly detached (Murphy 1994). This is an example of
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the latch state, where a low level of MLC-20 phosphorylation is associated with a high
maintenance of force and low corresponding expenditure of ATP (Huxley 1957). Another
suggestion allows that non-phosphorylated cross-bridges are attached with the assistance of
calponin and caldesmon (CaD) (Arner 1987; Khromov 1995; Somlyo 1988; Vyas 1992; Albrecht
1997; Matsui 1996) or that of already attached cross-bridges (Somlyo 1988; Somlyo 1990). In
addition, relaxation has been shown to occur while increased numbers of MLC-20 are still
phosphorylated (Barany 1993; Katoch 1997; McDaniel 1992; Tansey 1990). The relation
between the level of force and degree of phosphorylation may also depend on the type of agonist
used (Suematsu 1991).
Many kinases other than MLCK have been discovered to phosphorylate MLC-20,
including Rho-associated kinase, which phosphorylates MLC-20 in the peripheral region of the
cell (ROK) (Amano 1996; Miyazaki 2002), Integrin-linked kinase (Deng 2001), ZIP kinase
(Niiro 2001), MAPK (Takahashi 1998; Dessy 1998; Ohmichi 1997; Velarde 1999; Yousufzai
2000), Ca2+-Calmodulin Kinase II (CaM KII) (Pfitzer 1989), Protein Kinase C (PKC) (Lee 1999,
Katoch 1999), some unidentified staurosporine-sensitive kinases (Kureishi 1999; Iizuka 1999;
Weber 1999), and possibly some other unidentified kinases (Trinkle-Mulcahy 1995; Ichikawa
1996; Hartshorne 1998). The potency or relative importance of these kinases is not yet fully
understood, and can vary with the type of agonist used (Ganitkevich 2002).

Contraction Pathways in SM
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Figure 8: Diagram illustrating the signal transduction pathways involved in contraction of the SM cell.

Activation of MLCK by complexation with Ca-CaM causes it to phosphorylate MLC-20
and induce contraction. The affinity of MLCK for Ca-CaM can be decreased if it is
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phosphorylated. It has been shown to be phosphorylated by p42/p44 MAPK (Klemke 1997),
p21 activated protein kinase (PAK) (Sanders 1999), Cam KII (Tansey 1992), and cAMPdependent protein kinase (PKA), which causes 10-fold decrease in Ca2+-sensitivity (Conti 1981;
De Lanerolle 1984; Adelstein 1982), . It has also been found that the myosin binding region of
MLCK can bind to myosin heads and stimulate activation of the GTPase without
phosphorylation of MLC-20 (Gao 2003).
Inhibition of MLCP prevents it from dephosphorylating MLC-20 and causes an increase
in contraction. Activation of the phosphatase will, of course, lead to relaxation. Many Gproteins activate phospholipase A2 (PLA2), which cleaves arachidonic acid (AA)—a fatty acid
(FA)—from phospholipids (PLs). Arachidonic acid causes dissociation of the MLCP
holoenzyme into its constituent subunits: the regulatory subunit (MYPT-1), the catalytic subunit
(PP-1), and a 20 kDa subunit of unknown function (Gong 1992; Alessi 1992; Shirazi 1994;
Shimizu 1994; Haystead 1995; Gailley 1996; Harthorne 1998 [review]). The regulatory subunit,
which targets MLCP to MLC-20 remains in the cytosol, while the catalytic subunit translocates
to the cell membrane, where it experiences a reduced catalytic activity.

Relaxation Pathways in SM
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*Phosphorylation of MLCK at alternative sites causes:
-Decreased affinity for Ca-CaM
Figure 9: Diagram illustrating the signal transduction pathways of relaxation in SM cells.

MLCP is also inhibited by the phosphopeptide CPI-17, when it is activated by
phosphorylation (Harshorne 1998). It has been hypothesized that many kinases—ROK, PKC,
and ZIP-like kinase—phosphorylate and activate the peptide as a means of inhibiting MLCP
(Kanecko 2001; Eto 1995; Kitazawa 1999; Gailly 1997; (Macdonald 2001a; Ichikawa 1996a;
Pfitzer 2001; Trinkle-Mulcahy 1995).
Phosphorylation of the catalytic subunit (MYPT-1) of MLCP inhibits its function. This
task is performed by many kinases, including ROK (Feng 1999; Kimura 1996), ZIP-like kinase
(Ichikawa 1996; MacDonald 2001b), unidentified kinases sensitive to staurosporine-induced
contraction (Kureishi 1999, Weber1999), and other unidentified kinases (Feng 2000; Somlyo
1999).
In terms of activation, it has been proposed that either cGMP directly activates MLCP
(Surks 1999) or does so through phosphorylation of telokin, which activates MLCP (Wu 1998).
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IP3/DAG Signaling
Inositol-triphosphate (IP3), a negligible signal in skeletal muscle (Pape 1988), has been
confirmed as a secondary messenger in the contraction of smooth muscle by many sources
(Kobayashi 1989; Hashimoto 1986; Miller-Hance 1988; Somlyo 1992, 1988).

IP3/DAG Signaling in SM

Figure 10: Diagram illustrating the signaling pathways of IP3/DAG in SM cells.

Most excitatory agonists are coupled by G-proteins that activate phospholipase-beta
isoform (PLC-β), which cleaves phosphoinositol (PPI)—a phospholipid—into IP3 and
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diacyglycerol (DAG) (Figure 6). Generally, the G-proteins that activate the PLC-β pathway also
inhibit nucleotide cyclases, which will be discussed later (Somlyo 1994). Activators of PLC-β
include AA (Husain 1998, 1999), some tyrosine kinases (Zhou 1993), and phorbol esters (Jensen
1996; Walker 1998).

Figure 11: Structures of inositol-triphosphate (IP3) and diacylglycerol (DAG).

IP3 activates IP3-receptor Ca2+-channels in the SR (Somlyo 1994). DAG activates PKC,
which induces contraction by phosphorylating CPI-17, the MLCP inhibitor (Eto 1995; Kitazawa
1999; Gailly 1997). It can also phosphorylate the G-protein Raf, which acitvates MAPKK
(Neary 1997). Arachidonic acid can also activate PKC (Gong 1992, 1995).
IP3 can be phosphoryated by IP3 kinase to produce the inactive IP4. The IP3 receptor is
phosphorylated by cAMP-dependent protein kinase (PKA), cGMP-dependent protein kinase
(PKG), or CaM KII (Patel 1999). The pathway is also inhibited by heparin (Kobayashi 1989).
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On a side note, time delays between agonist-induced receptor activation and tension
development ranges from 200-500 ms. This delay is probably due to diffusion and reaction of
signaling molecules (IP3 production, diffusion of Ca-CaM). It is not limited by the act of MLC20 phosphorylation (Somlyo 1990).

cAMP/cGMP Signaling
The main secondary messengers for inducing relaxation are elevated levels of cAMP
(cyclic adenosine monophosphate) and/or cGMP (cyclic guanosine monophosphate) (Karaki
1988; Kerrick 1981; Morgan 1984; Pfitzer 1986; Seguchi 1996; van Riper 1995). Receptors are
activated and stimulate adenylyl/guanylyl cyclases, which catalyze the formation of
cAMP/cGMP from ATP (adenosine triphosphate) or GTP (guanosine triphosphate) precursors
(Pftizer 1984) (Figures 7and 8, below). Adenylyl cyclase is activated by many Gβγ-protein
receptors, and inhibited by many Gα-protein receptors. Some stimulants of relaxation through
the cAMP pathway include forskolin (Abdel-Latif 1996), Nitric oxide (NO), atrial natriuretic
peptide, and (ERF) (Lincoln 1996).

Figure 12: Conversion of Adenosine-triphosphate (ATP) into cyclic Adenosine-monophosphate (cAMP),
catalyzed by adenylyl cyclase.
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cGMP
Figure 13: Structure of cyclic guanosine-monophosphate (cGMP).

Cyclic Nucleotide (cAMP/cGMP) Signaling in SM

The effect of 4 × [cAMP] = [cGMP].
Figure 14: Diagram illustrating the signal transduction pathways of cAMP and cGMP in SM cells.
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cAMP activates cAMP-dependent protein kinase (PKA) and cGMP activate cGMPdependent protein kinase (PKG). There is evidence that cAMP may also activate PKG (Kotikoff
1996). Studies have also shown that four times the concentration of cAMP is required to cause
50% relaxation of vascular smooth muscle than cGMP (Dhanukoti 2000).
Increased levels of these cyclic nucleotides may cause reduction in cytosolic [Ca2+], via
1) Inhibition of PLC-β, and thus IP3 production, 2) Inhibition of Ca2+ channels, 3) Activation of
Ca2+ pumps in the PM and SR to remove Ca2+ from the cytosol (Abdel-Latif 2001). The
secondary messengers have also been shown to increase the frequency of Ca2+-sparks (Porter
1998).
PKA/PKG can phosphorylate and inhibit PLC-β (Abdel-Latif 1996; Liu 1996) if it is
anchored to the membrane by putative A kinase anchoring protein (AKAP86) (Dodge 1999).
PKA/PKG can phosphorylate the G-protein Raf which stimulates mitogen-activated protein
kinase kinase (MAPKK), but it is not clear whether this causes an inhibitory effect (Bornfeldt
1999; Cspedel 1999; Abdel-Latif 2001). Curiously, it has been found that cGMP may actually
activate MAPKK, but the implications of this are not known (Komalavilas 1999; Kim 2000; Ho
1999).
PKA/PKG is capable of phosphorylating the GTPase protein RhoA to inhibit the Rho
Kinase pathway, to be discussed later (Sauzeau 2000). PKA/PKG may also phosphorylate heat
shock protein 20 (HSP-20), which directly inhibits the MgATPase, causing relaxation (Rembold
2000).
The pathway may also inhibit contraction by activating MLCP through phosphorylation
of telokin, which activates the phosphatase (Wu 1998), and cGMP may activate MLCP directly
(Lee 1997).
RhoA/Rho Kinase Signaling
Another important regulatory and recently studied pathway that is independent of [Ca2+]
is the RhoA/Rho kinase (ROK) pathway. RhoA is a small GTPase that is inactive when bound to
GDP, and active when bound to GTP. Guanidine nucleotide dissociation inhibitors (GDIs) bind
to RhoA-GDP in the cytosol (Gosser 1997; Longenecker 1999). The exchange of GDP for GTP
is catalyzed by guanidine exchange factors (GEFs), which causes the GDI to dissociate (Kozasa
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1998; Hart 1998). This facilitates the translocation of RhoA-GTP to the PM (Gong 1997;
Fuijhara 1997; Read 2000; Cherfils 1999).

Rho Signaling in SM

Contraction = Tonic Phase Contraction
Bacterial Toxins (Reviewed-Sehr, 1998)
Clostridium Botulinum: ADP-ribosylation of RhoA at Asn-41
Clostridium Difficile: Monoglucosylates Thr-37 of RhoA
*Calcium-Independent Regulation of Contraction (Calcium Desensitization)
Figure 15: Diagram illustrating the signaling pathways associated with RhoA/ROK in SM cells.

Many trimeric G-proteins activate the RhoA pathway by stimulation of GEFs (Katoh 1998;
Croxton 1998; Klages 1999; Hirshman 1999). It has also been found that tyrosine kinase
inhibitors inhibit RhoA translocation to the PM, indicating that the pathway can be activated by
tyrosine kinase receptors, as well (Sakurada 2001). U-46619 has also been shown to activate the
pathway (Bradley 1987; Himpens 1988; Himpens 1990).
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The active RhoA-GTP activates Rho kinase (ROK). However, activation requires that
both units be translocated to the plasma membrane (Leung 1995; Gong 1997; Fujihara 1997;
Taggart 1999). ROK can also be activated by AA (Fu 1998; Feng 1999). ROK induces
contraction by phosphorylating and inhibiting MLCP (Kimura 1996; Feng 1999). ROK can also
phosphorylate calponin (Katoch 1997) and CPI-17, which inhibits MLCP, as well (Koyama
2000; Kanecko 2000).
Ca2+ sensitization facilitated by RhoA/ROK signaling only affects tonic SM contraction
(Somlyo 2000). Inhibition of the pathway results in relaxation. Several points of inhibition have
been observed. Some bacterial toxins can inhibit the translocation of RhoA-GTP to the PM.
The toxin from Clostridium botulinum causes ADP-ribosylation at asparagine 41 (Asn-41)of the
protein and that from Clostridium difficile causes monoglucosylation at threonine 37 (Thr-37) of
RhoA (Fujihara 1997; Gong 1997). Y-27632 is a specific inhibitor of ROK (Uehata 1997;
Somlyo 1997; Yoshi 1999; Fu 1998; Nakahara 2000). Rnd1 has properties that are antagonistic
to RhoA, and inhibits the pathway (Loirand 1999). Also, hydrolysis of GTP complexed with
RhoA to GDP, or re-complexation with GDI inhibits the pathway (Longenecker 1999).
It is interesting to note that the very specific Y-27632 ROK inhibitor has been shown to
reduce blood pressure in hypertensive rats, but has no effect on normal rats (Uehata 1997),
implicating that an overactive Rho pathway may cause some cases of high blood pressure. Use
of the inhibitor as a drug is being investigated (Somlyo 1997).
It has been proposed that ZIP-like kinase—known to phosphorylate MLCP, and
phosphorylate and activate CPI-17 (Macdonald 2001a; Ichikawa 1996a; Pfitzer 2001; TrinkleMulcahy 1995)—is a downstream link between PKC, ROK, and inhibition of MLCP. Two
problems for direct phosphorylation of MLCP by ROK occur. First, the major phosphorylated
site on MLCP is not inhibitory (Kitazawa 2002). Also, both RhoA-GTP and ROK are located at
the PM, and MLCP is cytosolic (Pfitzer 2001). Thus, ZIP-like kinase has been found to copurify with MLCP (Ichikawa 1996a), and is inhibited by ROK inhibitors and PKC inhibitors.
So, it has been proposed as the missing link between converging pathways (MacDonald 2001a).
MAPK Signaling
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Mitogen-activated protein kinase (MAPK) signaling has been more recently implicated in
SM contraction. p42/p44 MAPK can directly phosphorylate MLC-20 (Takahashi 1998; Dessy
1998; Ohmichi 1997; Velarde 1999; Yousufzai 2000; Dechert 2001). It was found that potent
inhibitors of the kinase inhibited PF2-induced contraction, but not IP3 production (Yousufzai
1998), leading to the postulation that direct phosphorylation of MLC-20 is most important
(Abdel-Latif 2001).

MAPK Signaling in SM

Figure 16: Diagram illustrating the signal transduction pathways associated with MAPK in SM cells.

MAPK signaling is induced by some G-protein receptors (Sah 2000). The complete
mechanism leading to the MAPK cascade is still unclear (Abdel-Latif 2001). However, they
may be facilitated by activation of the G-protein Ras, which activates Raf. Raf phosphorylates
MAPKK, which phosphorylates MAPK (Neary 1997).
p42/p44 MAPK can also phosphorylate MLCK (Klemke 1997) to increase its activity. It
has also been found to phosphorylate caldesmon (CaD) to cause its dissociation from F-actin.
The effect of this dissociation is not, however, believed to have a large influence on contraction,
as of now (Pearce 2003).
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Other Regulatory Proteins
Calmodulin Kinase II (Cam KII) is activated when complexed with Ca2+ at a higher
concentration than needed to activate MLCK (Tansey 1994). It can phosphorylate and inhibit
MLCK to serve as a source of negative feedback for levels of Ca2+ that are too high, thus
avoiding overconstriction (Word 1994). Autophosphorylation of Cam KII causes the effect to
continue after [Ca2+] levels have fallen (Somlyo 1994). Cam KII also activates MAPKK
(Katoch 1999).
Phorbol esters stimulate contraction when added to SM tissue, and were the agonist used
for studies conducted in this research, to be discussed later. They induce a modest increase in
the level of MLC-20 phosphorylation (Itoh 1993), through activation of PKC, possibly
phosphorylation of CaD (Adam 1992), or through activation of PLA2, and subsequent release of
AA. Slow phosphorylation of MLC-20, and slow development of tension at lower levels of
MLC-20 phosphorylation are associated with contraction induced by phorbol esters (Itoh 1993),
which has been proposed as an extreme case of latch (Somlyo 1994).
Caveolae
An interesting recent discovery is that of caveolae—specialized gathering platforms of
various shape. These platforms are composed of phopholipids and have been found in SM cells.
It has been suggested that these platforms serve as meeting centers for interacting regulatory
proteins involved in SM contraction, and are required for proper function of contraction, at least
(Taggart 2001). Severe contraction disorders were observed in mice with a deficiency in
caveolae (Drab 2001). Such caveolae may be important in other cell types and functions as well.
More research needs to be done.
Study of SM
As noted, SM demonstrates slightly different mechanistic properties. These properties
are a function of its ultrastructural design and the biochemistry of its proteins. This project was
begun in conjunction with colleagues Wright et al. from the Department of Physiology, Joan C.
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Edwards School of Medicine (MUSOM), for the purpose of providing a comprehensive, global
study of SM tissue. Wright et al. have investigated the mechanistic properties and dynamics of
SM activity (including cytoskeletal rearrangement/remodeling of actin/myosin filaments,
translocation of PKC within the cell, etc.) using confocal microscopy and methods similar to
those mentioned previously (see smooth muscle mechanics), (Recent publications: Dykes 2003;
Fulkz 2003; Wright 2002; Li 2002, 2001a, 2001b; Geng 2001a/2001b; Fulkz 2000; Fung 2000;
Battistella-Patterson 2000; Wang 2000).
This composition focuses on the biochemistry of SM tissue at the level of the proteome.
Operational behavior and regulation of the motor cross-bridges that facilitate motility and
contractile properties occurs at the molecular level.
The complexity of the multiple pathways explains why such slow progress has been
made on the understanding of signaling cascades in SM contraction. Different inhibitors and
agonists of contraction converge at different points in the pathways. Much research has been
done and is still being done on the effects of different agonists and receptor activation on
contraction/relaxation (for example: Lincoln 1996; Luo 1997; Yang 1998; Yang 1999; de
Alencar 2003. Reviews: Abdel-Latif 2001; Fernandes 2003; Koshimizu 2003).
Many traditional techniques have been utilized in the study of SM, such as cell culture
and transgenic animal models coupled with gene transfections, and site-directed mutagenesis (for
example: Yanboliev 2001; Cherie 2002; Hedges 2000, 1998; Dechert 2001). The physical
dynamics of depolarization, Ca2+ levels in the cell, and protein translocation have also been
probed, using such techniques as electrical field stimulation (EFS), patch clamps, and
fluorescence confocal microscopy (for example: ZhuGe 2000; Huang 2003; Wang 2003; Dykes
2003; Fultz 2003; Li 2002). However, a major problem with this microscopy is that fluorescent
indicator dyes must bind the cytosolic calcium in the cell. This binding removes Ca2+ from the
cytosol and may greatly perturb the homeostasis of the system, affecting the accuracy of
measured properties. Electron probe X-ray microanalysis allows the intracellular localization
and transport of cellular components to be monitored (Review: Somlyo 2000). Extensive
research is still conducted on the level of myosin phosphorylation, as well (for example:
Facemire 2000; Sobieszek 2001).
Proteomics
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Although progress has been made using such techniques, it has been slow progress.
Investigating each step individually takes more time. That is why it becomes necessary to
develop a means of investigation that utilizes a broader perspective of the biological system.
This investigation focuses on the analysis of signal transduction at the proteome level
through differential phosphorylation—the primary means of communication and activity
modification of proteins. Protein phosphorylation serves as the on/off signal for many, if not
most, of a cell’s activities. The proteomic approach coupled with mass spectrometry (MS)
analysis allows for high-throughput investigation of multiple proteins within a pathway, offering
a glimpse of the entire picture of cellular activities under a given set of conditions. It must be
emphasized that cellular communication does not occur linearly along a single pathway, but
branches into multiple associations of messenger molecules and proteins. The pathways are
interconnected.
This approach opposes the standard reductionist perspective of analysis in which isolated
steps or individual proteins/enzymes are investigated. Such considerations explain why it has
become necessary to incorporate the big picture into analysis. The proteome may be described
as the sum of proteins expressed by a specific cell or tissue type under given physiological
conditions. Proteins are the machinery which perform the vital functions that make life possible.
Dysfunctional proteins are frequently the pathogen behind many human disorders.
The human genome project (HGP) has provided a comprehensive starting point for
investigation. However, the genome provides only the blueprints for the cell’s activities,
furnishing a two-dimensional model that is often not straightforward. Not everything encoded in
the blueprint goes into the finished product, and modifications are made along the way. After
mRNA processing and post-translational modifications, the protein product is no longer
equivalent to its gene complement. Proteins are often manufactured as nonfunctional preproteins, often with signaling peptides that instruct where it should be shipped to in or outside
the cell. A peptide is clipped off the before the protein can fold correctly into the functional
product.
With the capabilities of modern proteomic techniques the entire proteome of a cell can be
viewed and investigated at once. Structural information and physical characteristics of proteins
can be obtained using proteomic/MS analysis (see Appendix II). In general, proteomics
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involves: 1) separation/isolation of proteins, 2) purification of analyte, and 3) analysis (see
Appendix III).
The proteomic techniques used in this study were based on methodology developed by
the research of Neal (2001) at Marshall University, with alteration of protocols, as necessary.
Phosphoproteomics
Phosphoproteins were specifically targeted for the purpose of this investigation. As has
been demonstrated and discussed in the preceding pathways, differential
phosphorylation/dephosphorylation is a very important means of signal transduction and
regulation in SM tissue. However, because of the standard analytical methods used thus far, few
of the actual phosphorylation sites within these proteins are known (Appendix VI).
Phosphoryation of a protein or peptide occurs at serine, threonine, and/or tyrosine
residues (Appendix V), and is mediated through a kinase. Dephosphorylation is catalyzed by a
phosphatase, (Figure 17).

Figure 17: Illustration of the phosphorylation/dephosphorylation of serine.

Specific methodology exists for the analysis of phosphopeptides/proteins, including 1 )
means of detection and identification of phosphomoieties, 2) allocation of phosphorylation sites,
3) selective isolation of phosphopeptides, and 4) derivitization of phosphopeptides/proteins.
Detection of phosphoproteins can be done on a 1D or 2D SDS-PAGE gel, either by specific
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phosphoprotein stains, such as the ProQ Diamond Phosphoprotein Stain by Molecular Probes
(Martin 2003), or via detection of autoradiography from cell lysates treated with radioactive
isotopes of phosphorous (P33, P32). The latter method was based on a SM phosphorylation study
done by Takuwa et al., in which several differentially phosphorylated proteins were noted, but
not identified (Takuwa 1988). This was the initial driving force for the approach. However, the
technique poses much more of a hassle due to the hazards and safety precautions associated with
working with radioactive materials. It is also more expensive due to the high cost of radioactive
P33. Both methods have been explored in this research.
After phosphoproteins are subjected to proteolytic digest by an endoprotease,
phosphopeptides can be selectively isolated through the use of Fe3+-IMAC (Immobilized metal
affinity chromatography) at relatively low expense. Phosphopeptides are negatively-charged
species that demonstrate a high affinity for Fe3+ (Posewitz 1999). Other negatively-charged
peptides—such as highly acidic peptides—are also bound by the IMAC. However, this problem
can be circumvented if carboxylic acid groups are esterified prior to IMAC separation (Ficarro
2002).
Low stochiometric abundance of phosphopeptides makes them more difficult to detect.
Pre-isolation of such peptides increases their relative abundance in mass spectra, as interference
of the more abundant non-phosphorylated peptides is removed. This methodology is known as
enrichment, and has been used in many applications (Cao 2000; Stensballe 2001; Ficarro 2002;
Raska 2002; Rocher 2003).
A condition for the analysis of phosphopeptides in positive ion mode is a low pH solution
(see Appendix II). An acidified solution will facilitate protonation of phosphate groups, and
allow molecular ions to obtain a net positive charge. Phosphoproteins normally carry a negative
charge, which makes them hydrophillic, as well. This makes reverse-phase HPLC less efficient,
which is set up to purify hydrophobic peptides. Therefore, it is best to purify phosphopeptides
on a special column, such as the POROS OligoR3 (Wilm 1996; Neubauer 1999).
Many other methods for characterization of phosphoproteins/peptides exist, but were not
investigated in this research. Direct dephosphorylation of peptides in triple quad mass
spectrometers is an excellent example of the capabilities of more advanced instrumentation.
Only a MALDI-TOF instrument was used in this work.
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Phosphopeptides can also be reacted with various agents to create an analyzable
derivative. Oxidation of the carbon-carbon (C-C) bond coupled with loss of the phosphate group
next to it is termed β-elimination. This reaction is usually facilitated by the alkaline metal
barium hydroxide (BaOH2), because of its greater efficiency at lower concentration than would
be required of sodium hydroxide (NaOH) (Figure 18). Serine, threonine, and carbamidocysteine
residues are also safe against hydrolysis by BaOH2, though free cysteines (CH3SH) and cystines
(CH3S-SCH3) are not (Bydford 1991).

Figure 18: β-elimination of phosphate groups from a peptide using a barium hydroxide (BaOH2) catalyst,
where Rc = C-terminal portion of peptide, and Rn = N-terminal portion of peptide.

Groups can then be added across the double bond via Michael addition to create useful
derivatives, such as 2-aminoethanethiol or ethanedithiol (Figure 19). Derivitized peptides can be
identified with MS and post source decay (PSD) (see Appendix II). The group can also be
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oxidized off, leaving a neutral peptide to help confirm identification (Cole 1967; Mega 1996,
1990; Adamczyk 2001; Goshe 2001Rusnak 2002; Steen 2002, 2003) (Figure 20).

Figure 19: Michael addition of the nucleophillic 2-aminoethylthiol across the double bond of the peptide, creating a
lysine-like residue, where Rc = C-terminus of peptide, and Rn = N-terminus of peptide.
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Figure 20: Oxidation of the lysine-like residue produces a sulfur-oxygen double bond which then dissociates from
the peptide, finally leaving an alanine residue.

Another exciting and innovative capability of this method lies in the capacity of the 2aminoethylcysteine derivatives (Figure 19) to be proteolytically cleaved by endoproteases
specific for lysine—trypsin. Subsequent analysis of the fragments with MS will allow
determination of phosphorylation sites within peptides with more than one serine/threonine
residue, because only a phosphorylated Ser/Thr residue will be derivitized and cleaved.
However, the technique is not useful for analyzing tyrosine phosphorylations.
In this research, the tonic phase of contraction, facilitated by prolonged exposure to an
agonist, was investigated using aortic SM tissue from Sprague Dawley rats. It should be noted
that due to prolonged exposure, functional remodeling of actin filaments and delayed relaxation
post-contraction can occur, as was investigated by our colleagues at MUSOM.
Differential phosphorylation in resting and phorbol-contracted (Figure 21) tissue was
probed using a phosphoproteomic approach coupled with MALDI-TOF MS. The goal was to
look at the whole proteome and the signal transduction pathways there involved.
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Figure 21: Structure of phorbol—the agonist used to contract the aortic SM tissue in this research.
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MATERIALS

Materials
COMPANY

MATERIALS

American National Corp. (Chicago, IL)

-Parafilm

Becton-Dickinson (Franklin Lakes, NJ)

-Polystyrene conical tubes (15/50 mL)

BioRad (Hercules, CA)

-Eppendorf pipets
-Ready gels

Fisher (Pittsburgh, PA)

-Redi-tips (1-10µL, 1-200µL, 1000µL)
- Alkacid pH test paper
- Microcentrifuge tubes (0.5 mL, 1.5 mL)

Genomic Solutions (Ann Arbor, MI)

-microtiter plates

Harvard Biosciences (Holliston, MA)

-DisposoBioDialyzers

Kimberly-Clark Corporation (Irving, TX)

-Kimwipes Ex-1

Millipore (Billerica, MA)

-ZipTips

Scientific Product (Cambridge, MA)

-Eppendorf pipets

Reagents
COMPANY

REAGENTS

Acros Organics (Pittsburgh, PA)

-Acetone
-Acetonitrile
-Acetic acid (HPLC grade)
-Glacial Acetic acid
-EDTA
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-Formic acid
-H2O2
-Isopropanol
-Iodoacetamide
-Methanol (HPLC grade)
-Sodium carbonate
BioRad Lab. (Hercules, CA)

-Silver stain plus kit
-SYPRO ruby protein gel stain
-Dithiothreitol
-Prestained Precision protein stds.
-Tris/Glycine/SDS buffer
-Laemmili Sample Buffer

Bruker-Daltonics (Billerica, MA)

-HCCA
-Sinapinic acid
-peptide calibration stds.

Fisher-Scientific (Pittsburgh, PA)

-Ammonium acetate
-Ammonium bicarbonate
-Ammonium hydroxide
-Dibasic sodium phosphate (Na2PO4)
-Monobasic potassium phosphate (KH2PO4)
-Dibasic potassium phosphate (K2H PO4)
- ethylenediaminetetraacetic acid (EDTA)
-Glycerol
-Magnesium chloride (MgCl2)
-Calcium chloride (CaCl2)
-Sodium bicarbonate (NaHCO3)
-Sodium chloride (NaCl)
-SDS
-Sodium thiosulfate
-Triethanolamine
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- Tris
-Potassium chloride (KCl)
-Potassium ferricyanide
-Urea
-pH buffer std solutions (pH 4.00, 7.00, 10.00)
Genomic Solutions (Ann Arbor, MI)

-Pre-cast duracryl slab gels
-Pre-cast carrier ampholyte pH 3-10 tube gels
-Pre-cast immobilized pH gradient pH 3-10
tube gels
-IEF Anode Concentrate (85% phosphoric acid)
-IEF Cathode Concentrate (10.0 N sodium hydroxide)
- IPG Urea/Thiourea Solubilization/Rehydration
Buffer
-Sample Buffer I
-Sample Buffer II
-Sample Buffer III
-Tris-acetate buffer—25x concentration
-Tris-acetate equilibration buffer
-Tris/Tricine/SDS running buffers

ICN Pharmaceuticals (Costa Mesa, CA)

-Actin (rabbit muscle)
-Ketamine
-Xylazine-20

Kodak

- XOMAT-AR film (8” × 10”) for autoradiography

Molecular Probes (Eugene, OR)

-ProQ Emerald 300 Glycoprotein stain Kit
-ProQ Diamond Phosphoprotein stain
-SYPRO Ruby Protein Stain

Pierce (Rockford, IL)

-GelCode Blue Protein Stain reagent

Sigma-Aldrich (St. Louis, MO)

-Brilliant Blue G (Coomassie Protein Stain)
-Trifluoroacetic acid
-Myoglobin
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-β-Mercaptoethanol
-Proteoprep Universal Extraction Kit
-Sodium Phosphate
-Trypsin—Proteomics grade

Instrumentation
COMPANY

INSTRUMENT

Applied Biosystems (Foster City, CA)

-130A Separation System HPLC

Barnstead (Boston, MA)

-Nanopure Infinity—Ultrapure water system

BioRad Lab (St. Louis, MO)

-Ready Gel Cell (1D SDS-PAGE)
-GelDoc w/ Quantity One software

Bruker-Daltonics (Billerica, MA)

-Biflex III (MALDI-TOF MS)

Denver Instruments (Denver, CO)

-M-220D Electronic Balance

Fisher-Scientific (Pittsburgh, PA)

-Dry Bath Incubator
-FS30 Sonicator
-Micro-7 Microcentrifuge
-Vortex Genie

Forma-Scientific (Marietta, OH)

-Lab/Pharmacy Freezer

Genomic Solutions (Ann Arbor, MI)

-ProGest Investigator (version 2.01.15)
-ProPic Ivestigator Imager/Robot picking w/
Investigator HT Analyzer software
-Investigator 2D Electrophoresis system w/
Investigator 5000 Programmable Power
Supply

Lab-Line Instruments (Boston, MA)

-Shaking bath

Savant Instruments (Holbrook, NY)

-SpeedVac SC110 vacuum microcentrifuge w/
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refridgerated vaportrap RVT 4104
-µSpeed Fuge SFR13K refridgerated
microcentrifuge
Thermo-Finnigan (San Jose, CA)

-LCQ
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BUFFERS AND SOLUTIONS
Krebbs Buffer (Incubation medium)

0.184 g CaCl2 x H2O
0.29 g MgCl2
6.90 g NaCl
0.35 g KCl
0.16 g KH2PO4
2.1 g NaHCO3
0.9 g glucose
-1 Liter H2O

Lysis Buffer

(37°C)

500 µL Tris (0.1 M)
500 µL Glycerol (1mg/mL)
10 µL EDTA (0.5M)
5 µL Lupeptin (1 mg/mL in PBS)
5 µL Pepstatin (17.4 mg/mL in EtOH)
5 µL Aprotinin (1 mg/mL in EtOH)
25 µL PMSF
-5 mL PBS

RIPA Buffer

50 mM Tris-HCl, pH 7.4
1% NP-40
0.25% Sodium Deoxycholate
150 mM NaCl
1 mM EDTA
1 mM PMSF
1 µg/mL aprotinin
1 µg/mL leupeptin
1 µg/mL pepstatin
1 mM Na3VO4
1 mM NaF

Phosphate Buffered Saline (PBS)

8.0 g NaCl
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0.2 g KCl
0.115 g Na2PO4
0.2 g K2HPO4
0.1 g CaCl2 (Anhydrous)
0.1 g MgCl2
-1 L H2O
Ketamine

100 mg/mL

Xylazine-20

20 mg/mL

Radioactive Phosphorous Solution

10 mCi P33/ 0.5 µL H3PO4

Phorbol Solution

10 nm Phorbol in DMSO
10 µm Phorbol in DMSO (Excess)

Proteoprep Universal Extraction Kit (SigmaAldrich)

-Soluble Cytoplasmic Extraction Reagent
-Cellular and Organelle Membrane
Solubilizing
Reagent
-Soluble Protein Resuspension Reagent

Dialysis Buffer I

1.84 g Tris
5.8 g NaCl
-1 L H2O

Dialysis Buffer II

Nanopure H2O

Laemmili Sample Buffer

62.5 mM Tris-HCl
2% SDS
25% Glycerol
0.01% Bromophenol blue

Tris/Glycine/SDS Buffer (1D SDS-PAGE)

25 mM Tris-HCl
192 mM Glycine
0.1% SDS

Sample Overlay Buffer

0.5 M Urea
0.2% Triton X-100
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0.1% Ampholytes
50 mM DTT
Sample Buffer I

(1/20 Sample Buffer Mix)

0.3% SDS
200mM DTT
28 mM Tris HCl
22 mM Tris Base

Sample Buffer II

(Store -70° C)

24 mM Tris Base
476 mM Tris HCl
50 mM MgCl2
1 mg/mL DNAse I

Sample Buffer III

(Store -70° C)

9.9 mM Urea
4% Triton X-100
2.2% Ampholytes
100 mM DTT

Sample Buffer Mix

(Store -70° C)

80 mL Sample Buffer III
+ 20 mL Sample Buffer I
7.92 M Urea
0.06% SDS
1.76% Ampholytes
120 mM DTT
3.2% Triton X-100
22.4 mM Tris HCl
17.6 mM Tris base

Modified Sample Buffer Mix

(Store -70° C)

Sample Buffer Mix
1.5% SDS
150 mM DTT

IEF Cathode Buffer (1st Dimension of 2D)

100 mM NaOH

IEF Anode Buffer

10 mM H3PO4

IPG Urea/Thiourea Solubilization/Rehydration

7 M Urea
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Buffer

2 M Thiourea
2% CHAPS
65 mM DTT
1% Zwittergent
0.01% Bromphenol Blue
0.80% Ampholytes (pH 3-10)

IPG Equilibration Buffer I

6 M Urea
130 mM DTT
30% Glycerol
45 mM Tris Base
1.6% SDS
0.002% Bromphenol Blue
--pH 7

IPG Equilibration Buffer II

6 M Urea
135 mM Iodoacetamide
30% Glycerol
45 mM Tris Base
1.6% SDS
0.002% Bromphenol Blue
--pH 7

Tris/Acetate Equilibration Buffer

0.112 M Tris
5 % SDS
0.1 % Bromophenol blue
50 mM DTT

2D SDS-PAGE Cathode (2nd Dimension of

0.2 M Tris

2D)

0.3 M Tricine

(Refridgerated)

0.4 % SDS

(Refridgerated)

2D SDS-PAGE Anode

25 mM Tris/Acetate

(Refridgerated)

Coomassie Brilliant Blue Stain

0.25 g Brilliant Blue R250
40 mL MeOH
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50 mL H2O
10 mL Glacial AcOH
Coomassie Fixing/Destain

(Filtered)

40% MeOH
50% H2O
10% Glacial AcOH

Silver Stain Fixing Solution

50% MeOH
10% AcOH
10% BioRad Fixative Enhancer Concentrate
(Silver Stain Plus Kit)
30% H2O

Silver Stain (BioRad Silver Stain Plus Kit)

15.0 mL Silver Complex Solution
15.0 mL Reduction Moderator Solution
15.0 mL Image Development Reagent
105 mL H2O
150 mL Development Accelerator Solution

Silver Destain

30 mM K2Fe(CH)6 in 100 mM Na2SO3

Silver Stain Stop Solution

5% AcOH

SYPRO Ruby Fixing/Destain Solution

10% MeOH
7% AcOH

SYPRO Ruby Protein Gel Stain

Use as is.

GelCode Blue Protein Stain

Use as is.

GelCode Blue Destain

H2O

ProQ Diamond Phosphoprotein Gel Stain

Use as is.

Phosphoprotein Fixing Solution

10% TCA

(Keep from light)

50% MeOH
Phosphoprotein Destain Solution

50 mM Sodium Acetate
4% AcCN

Tryptic Digest Solutions—Manual

Washing/swelling—100 mM NH4HCO3
Drying/shrinking—AcCN
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Reduction—10 mM DTT in 100 mM
NH4HCO3
Modification—55 mM Iodoacetamide in 100
mM NH4HCO3 (Light protected)
Digestion—2 µg/mL trypsin in 40 mM
NH4HCO3
Tryptic Digest Solutions—ProGest

Washing/swelling—40mM mM NH4HCO3
Drying/shrinking—AcCN
Reduction—10 mM DTT in 40 mM
NH4HCO3
Modification—100 mM Iodoacetamide in 40
mM NH4HCO3 (Light protected)
Digestion—20 µg/mL trypsin in 40 mM
NH4HCO3

HPLC Base Solvent

70% AcCN
0.85% Glacial AcOH
~30% H2O

HPLC Water Solvent

0.1% AcOH
~100% H2O

ZipTip (C-18) Solutions

Wetting—50% AcCN
Equilibration—0.1% TFA
Wash—0.1% TFA
Elution—70% AcCN in 0.1% TFA

MALDI-TOF Matrix Solutions (Two Layer

1st Layer solution—5 mg/mL HCCA in 50%

Spottin)

acetone
2nd Layer solution—Saturated HCCA in 50%
AcCN

*Solutions were prepared with >17 MΩ nanopure water.

METHODS
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*Procedures were performed at room temperature, unless specified otherwise in the
protocol.

I. Sample Preparation
Dissection/Tissue Extraction
Male Sprague dawley rats of approximately the same size and weight were anesthetized
with ~0.75 mL 2:1 Ketamine:Xylazine (100 mg/mL:20 mg/mL). Rats were obtained from
MUSOM, care of Dr. Gary Wright and/or Dr. William McCumbee. Filled the tip of a syringe
with ~20 mL heparin sodium, and drew blood from the heart, ~12 mL. Living aortic tissue was
then surgically removed, and thoroughly cleaned of any adherent material. Tissues were
temporarily stored/incubated in Krebbs buffer, 37°C.
Radioactive Phosphorous Labeling
Excised aortas were incubated in phosphate-free Krebbs buffer after extraction from the
chest cavity at 37C. One hundred microliters of H3PO4 was added to dilute a 1 µL aliquot of __
mCi H333P04. All of the diluted radioactive phosphorous solution was added to the Krebbs
buffer surrounding the aortas. The mixture was allowed to incubate for ~3.5 hours, to allow for
cell uptake and chemical exchange of 31P for the radioactive 33P. All procedures were
performed in designated radioactive work areas.
Phorbol Incubation
Aortic tissue was incubated in 37°C Krebbs buffer. Excess phorbol agonist was added to
stimulate contraction—25 µL of 10-5 M phorbol in DMSO per ~2.5 mL Krebbs buffer. Tissue
was incubated ~0.5 hrs to facilitate a prolonged exposure to the contractile agonist.

Cell Lysis
PROCEDURE 1
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Cells were lysed in 0.5-1.0 mL, depending on amount of tissue, chilled lysis buffer with
grinding to homogenize tissue. Homogenate was then centrifuged at 12,000 RPM, ~12 min.
The supernatant was collected as the aqueous protein extract.
PROCEDURE 2
Cells were lysed in 0.5 mL chilled RIPA lysis buffer, containing phosphatase inhibitors,
with grinding to homogenize tissue. Homogenate was centrifuged at 12,000 RPM, ~12 min.
The supernatant was collected as the aqueous protein extract, with lyophilization to concentrate,
as necessary. The pellet was saved for extraction of membrane proteins.
Solubilization of Membrane Proteins
PROCEDURE 1
The pellet was boiled in 10% SDS to solubilize membrane proteins, ~10 min. The
supernatant was collected as the membrane protein extract.
PROCEDURE 2
The pellet was boiled in sample buffer I, 100°C for ~5 min. The mixture was vortexed, and
boiled again ~5 min. The mixture was centrifuged 12,000 RPM, ~10 min. The supernatant was
collected as the membrane protein extract.
PROCEDURE 3
Genomic Solutions Protocol—The pellet was boiled in sample buffer I, 100°C for ~7 min.
The mixture was then chilled on ice. Fourty-five microliters of sample buffer II, containing
RNAse and DNAse, were added. The mixture was chilled on ice ~8 min with sonication. Nine
hundred microliters of acetone were added to produce an 80% v/v solution. The mixture was
chilled on ice ~20 min. Then, the mixture was centrifuged at 10,000 RPM, ~15 min. The
supernatant was removed, and the pellet was allowed to dry. The pellet was then redissolved in
sample buffer mix.
PROCEDURE 4
Sigma ProteoPrep Universal Extraction Reagent—One milliliter of soluble cytoplasmic
protein reagent was added to the pellet. The mixture was sonicated on ice, ~5 min, and then
centrifuged at 4°C, 13,000 RPM for 45 min. The supernatant was collected as the aqueous
membrane protein extract, which was then lyophilized to dryness, and redissolved in the soluble
protein resuspension reagent. The pellet was redissolved in 1 mL of the cellular and organelle
46

membrane solubilizing reagent, and warmed to room temperature. The mixture was vortexed
and sonicated, ~10 min, and then centrifuged at 13,000 RPM, ~45 min at 4°C. The supernatant
was collected as membrane protein extract.178

II. Sample Purification
Acetone Precipitation
Ice cold acetone was added to the supernatant and to the pellet to solubilize and wash
away unwanted contaminants, leaving a more pure protein precipitate. The pellet was then
redissolved in sample buffer mix, ready for gel electrophoresis.
Dialysis
One hundred µL of sample mixture were loaded into a DisposoBiodialyzer unit from
Harvard Biosciences. Air bubbles were removed from the surface of the dialysis membrane as
the unit was placed into the dialysis buffer. Samples were dialyzed overnight in either dialysis
buffer I or dialysis buffer II, with at least one change of buffer.

III. Separation/Isolation of Proteins
1D SDS-PAGE
A 1D gel apparatus from BioRad was used to facilitate 1D SDS-PAGE. All parts of the
apparatus should be sufficiently cleaned and rinsed with nanopure water. Samples were mixed in
a 1:1 ratio with Laemmili Sample Buffer to reduce the sample. Samples were then heated to 95º
for approximately 3 minutes. Tris/Glycine/SDS running buffer was added to the tank of the
apparatus to serve as both the anode and cathode buffer. Fifteen to twenty µL of the sample
mixture was loaded into the well of the gel. Every other well was used to avoid crosscontamination of proteins during propagation through the gel. Prestained MW standards from
BioRad were loaded into the wells at each end of the gel. Gels were subjected to 100 V for ~4590 minutess, or until the blue dye front reached the bottom of the gel.
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2D SDS-PAGE
A 2D gel apparatus from Genomic Solutions was used to facilitate 2D SDS-PAGE. All
parts of the apparatus should be sufficiently cleaned and rinsed with nanopure water. Eleven
liters of freshly prepared of SDS-PAGE anode buffer was poured into the lower tank of the slab
gel apparatus. The cooling plate was turned on to allow the buffer to cool overnight. Three liters
of freshly prepared SDS-PAGE cathode solution was refridgerated overnight, as well.
1st Dimension Separation
Tube Gel Procedure
IEF anode buffer was poured into the tank of the IEF apparatus. The tube gel apparatus
was lowered into the tank. One tube gel per sample was installed into the apparatus, with
removal of air bubbles from both sides of the tube with a syringe filled with the appropriate
anode or cathode solution. Approximately 50 µL of sample overlay buffer was then loaded into
each tube gel. Samples were mixed 1:1 with sample buffer mix, if not already solubilized in this
buffer. Fifty µL of the sample mixture was loaded into the tube gel. Eight hundred milliliters of
IEF cathode buffer was poured into the upper chamber of the apparatus. Gels were focused for
17.5 hours at a maximum voltage of 2000 V and a maximum current of 110 µA per gel.
Tube gels were placed on ice for ~10 minutes. Tube gels were then extruded into ~2 mL
of IEF equilibration buffer, and allowed to incubate for no more than 2 minutes. Tube gels were
loaded onto slab gels for second dimension separation.
IPG Strip Procedure
Four hundred microliters of IPG urea/thiourea solubilization/rehydration buffer was
added to the protein precipitate obtained from the acetone precipitation. This mixture was
distributed evenly between the electrodes of the pHaser tray. IPG strips were placed gel-side
down over top of the mixture, removing air bubbles from underneath the strip. Tray was placed
in a plastic bag with a piece of moistened filter to keep gels from drying out. Samples were
allowed to rehydrate for ~16 hours.
The pHaser tray was placed into the voltage housing unit. The unit was set on top of a
chiller. A moistened wick was placed between the electrodes and the ends of the gel strips.
Approximately two milliliters of mineral oil was spread over the top of the strip. Strips were
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focused for 24.5 hours with a maximum voltage of 5000 V and a maximum current of 80 µA per
gel. The temperature was maintained between 15-20 °C during focusing. Wicks were replaced
every hour for three hours to aid in the removal of salts.
IPG strips were placed in ~10 mL IPG equilibration buffer I and agitated for ~10
minutes. The buffer was discarded and this step was repeated. The buffer was discarded and
~10 mL of IPG equilibration buffer II was added to the tray. The strips were agitated for ~10
minutes. Strips were removed from buffer and loaded onto slab gels for second dimension
separation.
2nd Dimension Separation
The 2D SDS PAGE anode and cathode buffers were previously chilled overnight. The
tank of the slab gel was filled with 11 L of 2D SDS PAGE anode buffer. Grooves of slab gels
(housing the tube gels or IPG strips) were filled with 2× 2D SDS PAGE cathode buffer. Slab
gels were loaded into the slab gel apparatus, securing grommets around slab gel to prevent
leakage of solutions. The slab gel apparatus was lowered into the tank. The upper chamber of
the apparatus was filled with three liters of 2D SDS PAGE cathode buffer. A maximum of 500
Volts was applied across the gel for approximately 4.5-5 hours, or until the blue dye front
reached the bottom of the gel. Gels were removed from cassettes and washed in nanopure water
for 10 minutes with one change of water.

IV. Analysis
Visualization of Protein Bands
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Autoradiography
2D gel with proteins was wrapped in plastic wrap and placed into an autoradiography
cassette. In the dark, a piece of XOMAT-AR film paper was placed on top of the gel. The
cassette was closed and sealed that no light could get into the cassette. Gels were exposed for 12
hours for the first trial, and then 36 hours for the second trial.
Gel Staining
GelCode Blue Protein Stain
One dimension protein gels were agitated in GelCode Blue protein stain for three hours.
The solution was removed. Gels were then agitated in nanopure water to reduced background
staining. Gels were imaged with a visible light source.
Phosphoprotein Stain
Gels were agitated in ~500 mL of phosphoprotein fixing solution for one hour with one
change of fixing solution. The solution was removed. Gels were then washed with ~500 mL of
nanopure water for ~15 minutes to remove the methanol and acetic acid from the gel. This step
was repeated three times. Gels were agitated in 500 mL of ProQ Diamond Phosphoprotein Gel
Stain in the dark for four hours. The solution was removed, and gels were agitated in
phosphoprotein destain solution in the dark for a total of four hours with three changes of destain
solution. Gels were imaged with a visual source.
Coomassie Brilliant Blue Protein Stain
Gels were agitated in ~500 mL of Coomassie fixing/destain solution for one hour to fix
proteins to gel and remove any remaining SDS from the gel. The solution was discarded. Gels
were then agitated in ~500 mL of Coomassie Brilliant Blue stain overnight. The solution was
removed, and ~500 mL of Coomassie fixing/destain was added. Gels were agitated in destain
for one hour. The destaining step was repeated up to four times to remove enough background
stain for protein bands to be effectively visualized. Gels were imaged with a visual light source.
SYPRO Ruby Protein Gel Stain
Gels were agitated in ~500 mL of Ruby fixing/destain solution for 30 minutes. The
solution was removed. Gels were then agitated in ~500 mL SYPRO Ruby protein gel stain
overnight. The solution was discarded, and gels were agitated in ~500 mL of SYPRO Ruby
fixing destain solution for 30 minutes. Gels were imaged with a UV light source.
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Silver Stain
Gels were agitated in ~800 mL of silver fixing solution for 30 minutes. The solution was
removed. Gels were then washed with nanopure water for 20 minutes with agitation. This step
was repeated. The silver stain was prepared fresh immediately prior to use, and gels were
agitated in stain for ~20 minutes, or until protein bands were effectively visualized. The solution
was removed, and the silver stop solution was added immediately. Gels were imaged with a
visual light source.
Gel Imaging
Gels were imaged and analyzed using either the BioRad GelDoc Imager or the Genomic
Solutions ProPic Investigator Imager. Either a visible or UV light source was used to image the
gels, according to that required by the excitation/emission wavelength of the method of staining.
Proteolytic Digest of Proteins—In Gels (Tryptic Digest)
Protein bands were excised from the gel either by hand for manual excision or by the
Genomic Solutions ProPic Investigator for automatic excision. For silver stained gels, excised
bands were incubated in silver destain solution for 30 minutes. This solution was then removed
and bands were washed three times with nanopure water for a total of 30 minutes, 10 minutes
between changes of water.
Gel bands were incubated in AcCN for 10 minutes to destain and/or dehydrate gel pieces.
Gel bands were then lyophilized in a SpeedVac to remove the AcCN. A reducing buffer of 10
mM DTT in 100 mM NH4HCO3 was added to the gel pieces, which were then incubated for one
hour at 56°C.
The solution was discarded and gel bands were allowed to cool to room temperature. A
modification buffer of 55 mM iodoacetamide in 100 NH4HCO3 was added to the gel pieces,
which were then incubated at room temperature in the dark for ~45 minutes.
The solution was discarded and gel pieces were washed with 100 mM NH4HCO3 for 20
minutes. This solution was discarded and gel pieces were dehydrated with AcCN. The AcCN
was removed. These steps were repeated. Gel pieces were then lyophilized to remove all AcCN.
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Twenty microliters of a 2 µg/mL (pH 8.5) solution of modified trypsin in 40 mM NH4HCO3 was
added to the gel pieces. The trypsin was allowed to digest the proteins overnight at 37°C to
cleave the protein at arginine and lysine amino acid residues.
The supernatant was collected. Peptide fragments were extracted with one change of 20
mM NH4HCO3 and three changes of 5% formic acid in 50% AcCN. All washes were collected,
and the solution was lyophilized in a SpeedVac to necessary volumes.
Desalting
Reverse Phase HPLC
Fifty microliters of the sample was loaded into the HPLC injection port. For protein
samples, a C-4 column was used, and for peptide samples, a C-18 column was used. Samples
were passed over the appropriate column. Salts and contaminants were washed through the
column with 0.1% AcOH. Proteins/peptides were eluted off the column with a gradient increase
of 70% AcCN in 0.085% AcOH. A UV/Visible wavelength spectroscopic detector set at 214 nm
was used to detect the amine groups of the proteins/peptides. The eluant was lyophilized in a
SpeedVac to approximately two microliters in preparation for MALDI-TOF MS. If samples
were lyophilized to dryness, they were redissolved in 5% formic acid in 50% AcCN.
Ziptip desalting
Samples were previously concentrated to 10 µL of volume, or were redissolved in 10 µL
of 0.1% TFA if dry. A ziptip was attached to an eppendorf pipette. For proteins, a C-4 packed
tip was used, and for peptides, a C-18 packed tip was used. The ziptip was wetted by aspirating
10 µL of wetting solution. The ziptip was then equilibrated by aspirating 10 µL of
equilibration/wash solution. Proteins/peptides were bound to the beads of the tip by aspirating
the sample mixture for 10-15 cycles. The sample was washed by aspirating 10 µL of
equilibration/wash solution three times. Proteins/peptides were eluted with 20 µL of elution
solution, followed by a third exctraction of 100% AcCN to remove all proteins/peptides from the
tip. The eluant was lyophilized in a SpeedVac to approximately two microliters in preparation
for MALDI-TOF MS. If samples were lyophilized to dryness, they were redissolved in 5%
formic acid in 50% AcCN.
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MALDI-TOF Analysis
Spotting
Samples were spotted using the two layer method of spotting to ensure homogenous spots
of samples. A volume of 0.7 µL of the first layer solution was spotted onto the MALDI probe to
create a homogenous layer of matrix. The volatile solvent assures fast evaporation.
Concentrated and desalted samples were mixed 1:1 with the second layer solution, with
aspiration to mix. A volume of 0.7 µL of this mixture was spotted on top of the dried first layer.
This layer was allowed to dry before the MALDI probe was inserted into the instrument.
Calibration
External Calibration
A Bruker Biflex III MALDI-TOF MS was used for analysis in this investigation. The
instrument was calibrated in the peptide fingerprint range using a sample of peptide standards of
known m/z value. The standards were stored in a solution of 0.1% TFA, and spotted on the
MALDI probe according to the procedure outlined above. A linear calibration was performed
using the monoisotopic m/z values of the standards listed in table 2.
External calibration was performed immediately preceding acquisition of data for sample
analysis. It is important that a calibration be performed if any of the parameters of the
instrument are changed—voltage, laser power, etc.—prior to acquisition of data.

Calibration Standards
Peptide Standard

M/Z Value

Angiotensin II

1046.542

Angiotensin I

1296.685

Substance P

1347.736

Bombesin

1619.823
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ACTH clip 1-17

2093.086

ACTH clip 18-39

2465.199

Somatostatin-28

3147.47

Table 2: List of the peptide standards and corresponding m/z peak values used for external and internal calibration
of MALDI spectra.

Internal Calibration
An aliquot of the sample mixture was spotted on the MALDI probe as outlined above.
One microliter of a 1/20 dilution of the peptide standards from table 2 was added to the
sample:matrix solution , with aspiration to mix. This mixture was then spotted as the second
layer in the spotting method outlined above.
A suitable spectrum was collected for each spot. The spectrum containing the standards
was calibrated using the correct m/z values for the standard peaks. Then, three to four sample
peaks that spanned a range representative of the sample spectrum were selected to calibrate the
spectrum from the sample. These peaks were matched to their corresponding peaks in the
uncalibrated spectrum, and used to calibrate this spectrum.
Data Acquisition
Samples were analyzed on a Bruker Biflex III MALDI-TOF MS. Analysis was
performed in reflectron mode (see Appendix II) in the range of 500 to 4000 Da. The delayed
extraction time period was set to medium. Preliminary data from a sample spot was collected to
fine tune the attenuation of the laser power and IST voltages of the instrument to a level which
provided the best spectrum. The instrument was then calibrated externally under these
parameters.
The sample spot was searched for an area which gave the highest S/N ratio peaks. Then
an averaged spectrum of ~100 laser shots was collected. This was done for each sample to
provide digest (peptide fingerprint) spectra for each.
Post Source Decay (PSD)
The instrument was externally calibrated according to the procedure outlined above. A
standard sample spot of ACTH clip 18-39 was used to calibrate the instrument. The ion gate was
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set to the m/z value for the standard to deflect unwanted particles (see Appendix II). A suitable
spectrum was collected for each mass range afforded by the KE filter. Various parameters were
manipulated—deflection time, IS/T voltages, laser power—to optimize the conditions of the
instrument to provide the best spectra. The series of pre-pasted spectra were collected for the
standard, and then compared by the instrument to the known m/z fragmentation values of the
standard. The instrument was calibrated in this manner to produce the final calibrated
fragmentation spectrum.
The m/z of the peptide to be analyzed was set in the ion gate. The sample spectra were
collected in the same way as the standard. Data was acquired under the same parameters as the
standard to maintain calibration.
Identification of Unknown Proteins/Protein Database Searching (MASCOT)
Peptide fingerprints of proteins were matched to those found in online protein databases
using the MASCOT search engine from Matrix Science of London237, using the specifications
listed in table 3, below.
Missed

Cystine

Methionine

M/Z Mass

Cleavages

Modifications

Modifications

Range

Up to 2

Carbamidomethyl

Oxidized

2 Da

Taxonomy
Rodentia

(Acetamide)
Table 3: List of the specifications entered into the search form of the MASCOT search engine protein database.

Contaminating trypsin peaks were first eliminated from the peak list. Trypsin peaks were
determined from a peptide fingerprint map of a theoretically digested trypsin protein with
dimethylated lysines and oxidized methionines and/or from a self-digested mixture of trypsin
and a blank piece of gel, as performed in the laboratory at Marshall University.
Once the matching fingerprints were identified using MASCOT, likely protein candidates
were produced by the database search engine. The peptide fingerprint of the smooth muscle
isoform of the putative protein, if available, may have been compared manually to the sample’s
spectra to look for possible phosphorylation sites or other modifications, assuming the putative
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protein produced was within the correct molecular weight range estimated from the position of
the protein band on the 2D gel and the score of the putative match is significant.
The search engine matches peaks and uses a probability function to provide a score. The
score is a representation of the probability that a correct match has been obtained, (equation __).
MASCOT score = -10 log P

(19)

where P = the probability that the match could occur randomly in nature. Only those candidates
with significant scores (>56) were reported in the results section of this work.
The website search engine also provides a percentage of the protein’s amino acid peptide
fragment sequence covered by the m/z peak list entered into the database.

RESULTS AND DISCUSSION
The primary objective of this work focused on the analysis of differential protein
phosphorylation between resting and contracted aortic SM tissue using proteomic techniques and
MALDI-TOF mass spectrometry. It was hoped that this versatile technique coupled with the
application of protein database information would help clarify the signal transduction pathways
at work in smooth muscle tissue. However, many challenges were encountered in pursuit of this
goal, so that the body of this discussion focuses, instead, on the development of protocol for the
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analysis of phosphoproteins. Many problems have been investigated and resolved, while some
difficulties remain. These difficulties limit the scope of this research.
2D Gel Electrophoresis
The quantity of proteins separated and visualized on a 2D gel using tube gel IEF focusing
was found to be too low to allow adequate sample analysis. A tube gel apparatus was initially
used to focus proteins based on their pI in the first dimension separation of the 2D
electrophoresis. The maximum quantity of protein that may be loaded into the tube gel is 100
µg, dissolved in 50 µL of buffer. The 2D gels obtained by this method had to be stained with the
more sensitive stains, such as silver stain or SYPRO ruby stain with a limit of detection near 1
ng, to allow any type of visualization. Staining with the colloidal Coomassie blue stain (limit of
detection—1 µg) proved to be insufficient.
Some gels showed very little visualization of protein bands even with such sensitive
stains. Figures 22-32 depict gels stained with the more sensitive silver stain and SYPRO ruby
protein gel stain. A considerable amount of nonspecific or artifact staining (blots of stain that do
not represent protein bands) can be seen on those gels stained with silver stain.

2D_7_24_01_Phorbol_sup
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Figure 22: Example of a 2D gel containing supernatant or aqueous proteins from phorbol-contracted
aortic SM tissue stained with silver stain, revealing very little evidence of protein bands.

2D_7_30_02_Control
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Figure 23: Example of a 2D gel containing supernatant or aqueous proteins from resting aortic SM tissue
stained with silver stain, revealing very little evidence of protein bands.

2D_10_09_02_Control
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Figure 24: Example of a 2D gel containing supernatant or aqueous proteins from resting aortic SM tissue
treated with RNAse and DNAse prior to electrophoresis. This gel was stained with silver stain, and reveals very
little evidence of protein bands.

2D_10_09_02_Phorbol

Figure 25: Example of a 2D gel containing supernatant or aqueous proteins from phorbol-contracted
aortic SM tissue treated with RNAse and DNAse prior to electrophoresis. This gel was stained with silver stain, and
reveals very little evidence of protein bands.
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2D_10_09_02_Control_Pell

Figure 26: Example of a 2D gel containing membrane proteins from resting SM tissue, where proteins
were solubilized in boiling 10% SDS and treated with RNAse and DNAse prior to electrophoresis. This gel was
stained with silver stain, and reveals very little evidence of protein bands.
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2D_10_09_02_Phorbol_Pell

Figure 27: Example of a 2D gel containing membrane proteins from phorbol-contracted SM tissue, where
proteins were solubilized in boiling 10% SDS and treated with RNAse and DNAse prior to electrophoresis. This
gel was stained with silver stain, and reveals very little evidence of protein bands.

2D_6_18_02_Control

Figure 28: Example of a 2D gel containing supernatant or aqueous proteins from resting aortic SM tissue
stained with SYPRO ruby protein gel stain, revealing very little evidence of protein bands.
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2D_6_18_02_Phorbol

Figure 29: Example of a 2D gel containing supernatant or aqueous proteins from phorbol-contracted
aortic SM tissue stained with SYPRO ruby protein gel stain, revealing very little evidence of protein bands.

2D_7_12_02_Control
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Figure 30: Example of a 2D gel containing supernatant or aqueous proteins from resting aortic SM tissue
stained with SYPRO ruby protein gel stain, revealing very little evidence of protein bands.

2D_7_12_02_Phorbol
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Figure 31: Example of a 2D gel containing supernatant or aqueous proteins from phorbol-contracted
aortic SM tissue stained with SYPRO ruby protein gel stain, revealing very little evidence of protein bands.

2D_7_30_02_Phorbol

65

Figure 32: Example of a 2D gel containing supernatant or aqueous proteins from resting aortic SM tissue
stained with silver stain.

Overall, silver staining provided the best visualization of protein bands. However,
because of the low quantity of protein per band, limited success was achieved for analysis by
tryptic digest and subsequent MS analysis. Many of the averaged digest spectra obtained from
these gels were of poor signal to noise (S/N) ratio. Examples of these types of digest spectra can
be seen in figures 33-45, below. The location of the digested bands on the corresponding 2D gel
may be seen in the figures, above.
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Figure 33: Example of an averaged tryptic digest spectrum obtained from protein band 8C the gel 2D_7_30_02
Control, revealing low S/N ratios for peptide peaks.

Figure 34: Example of an averaged tryptic digest spectrum obtained from protein band 4P the gel 2D_7_30_02
Phorbol, revealing low S/N ratios for peptide peaks.
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Figure 35: Example of an averaged tryptic digest spectrum obtained from protein band 5C the gel 2D_7_30_02
Control, revealing low S/N ratios for peptide peaks.

Figure 36: Example of an averaged tryptic digest spectrum obtained from protein band 2P the gel 2D_7_30_02
Phorbol, revealing low S/N ratios for peptide peaks.

68

Figure 37: Example of an averaged tryptic digest spectrum obtained from protein band 2C on the gel 2D_7_12_02
Control, revealing low S/N ratios for peptide peaks.

Figure 38: Example of an averaged tryptic digest spectrum obtained from protein band 3C on the gel 2D_7_12_02
Control, revealing low S/N ratios for peptide peaks.
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Figure 39: Example of an averaged tryptic digest spectrum obtained from protein band 1P on the gel 2D_7_12_02
Phorbol, revealing low S/N ratios for peptide peaks.

Figure 40: Example of an averaged tryptic digest spectrum obtained from protein band 2Pon the gel 2D_7_12_02
Phorbol, revealing low S/N ratios for peptide peaks.
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Figure 41: Example of an averaged tryptic digest spectrum obtained from protein band 18C on the gel
2D_10_09_02_Control, revealing low S/N ratios for peptide peaks.

Figure 42: Example of an averaged tryptic digest spectrum obtained from protein band 24C on the gel
2D_10_09_02_Control, revealing low S/N ratios for peptide peaks.
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Figure 43: Example of an averaged tryptic digest spectrum obtained from protein band 15P on the gel
2D_7_30_02_Phorbol, revealing low S/N ratios for peptide peaks.

Figure 44: Example of an averaged tryptic digest spectrum obtained from protein band 7CP on the gel
2D_10_09_02_Control_Pell, revealing low S/N ratios for peptide peaks.
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Figure 45: Example of an averaged tryptic digest spectrum obtained from protein band 6CP on the gel
2D_10_09_02_Control_Pell, revealing low S/N ratios for peptide peaks.

Because of such difficulties, the focus of the research was simplified to mapping the
proteome through identification of proteins on the gel in resting SM tissue in attempt to confirm
the protocol.
Other explanations for the production of inadequate gels have been investigated. Poor
solubilization of proteins was suggested as one possible explanation for this phenomenon. Many
different methods of protein solubilization were attempted with little improvement of protein
band intensity and subsequent data acquisition.
The cellular extract was first boiled in 10% SDS to help denature and solubilize all
proteins. Protein concentration was not high enough for visualization with Coomassie, and had
to be stained with silver stain (Figure 46). Though bands were visualized for this method, no
identifications were made from the data collected for this gel.
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2D_7_12_01_Phorbol_pell

Figure 46: Example of a 2D gel containing membrane proteins solubilized with boiling in 10% SDS, from
phorbol-contracted aortic SM tissue stained with silver stain.

At one point, it was believed that too much cellular debris (RNA, DNA, etc.) existed in the
sample mixture to allow adequate migration within the tube gel, even though a chelating agent
(EDTA) was added to the lysis buffer to chelate the negatively charged DNA/RNA in the
sample. Samples were treated with RNAse and DNAse enzymes prior to separation, but this did
not appear to improve sample migration (Figures 24-27).
It was also proposed that too much salt in the sample mixture prevented efficient IEF
separation in the tube gels. Therefore, samples were thoroughly dialyzed prior to separation to
remove salt contamination. Salts are naturally present in biological samples, and they may also
have been introduced to the sample during cell lysis (RIPA buffer) or when tissue was incubated
in salt-containing buffers (Krebbs buffer, PBS). Samples were dialyzed for extended periods of
time—overnight—with several changes of different dialysis buffers, both a low salt dialysis
buffer (dialysis buffer I) and nanopure water. Dialyzed samples were always lyophilized prior to
1st dimension separation to concentrate the protein, as well. However, 2D gels with adequate
protein concentration were never obtained (Figures 24-32). Finally, protein extracts were
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submitted to acetone precipitation to remove salt/detergent contaminates and other cellular
debris to purify the protein extract prior to electrophoresis (Figures 51 and 52).
It was concluded that tube gel separation did not allow an adequate amount of protein to
pass into the tube gel, and thus inhibited proper 2D gel sample analysis. The tube gel holds only
50 µL of solubilized protein. Despite several attempts to concentrate and remove salt
interference, little improvement was ever observed.
To further support this conclusion, sample extracts of both the contracted and
uncontracted tissue were run on a 1D gel to facilitate analysis (Figure 47). From this gel, the
presence of actin and tropomyosin were detected. Band 1C was found to be tropomyosin with a
MASCOT score of 63. The placement of the band on the gel agrees with the MW of
tropomyosin (~33 kDa). Band 2C and 2P were identified as actin with MASCOT scores of 107
and 81, respectively. Their approximate MW on the gel also agrees with that of actin (~42
kDA). The digest spectra, peak lists, and MASCOT analysis data can be seen below (Figures
48-50, Table 4). No further identifications were made from this gel.

Figure 47: 1D gel stained with Coomassie Brilliant Blue protein stain, depicting the location of excised bands 1C,
2C, and 2P submitted to tryptic digest and MS analysis for successful identification. Control-SuP = resting aortic
SM tissue. Phorbol-Sup = phorbol-contracted aortic SM tissue.
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832.536
1036.657
1044.694
1073.715
1107.670
1165.822
1170.848
1179.767
1186.847
1243.814
1298.930
1314.893
1326.796
1399.897
1475.884
1790.993
1874.029
1994.071
2064.248
2085.133
2210.216
2333.256
2365.292
2384.089

Figure 48: Tryptic digest spectra and generated peak list of excised protein band 1C from the gel 1D-6-13-02,
above. This peak list was searched in MASCOT, which identified it as tropomyosin with a score of 63.

945.639
976.524
1130.625
1198.773
1483.711
1499.718
1514.758
1790.879
1955.997
1974.881
2228.077
2356.180
2725.389
3196.656
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Figure 49: Tryptic digest spectra and generated peak list of excised protein band 2C from the gel 1D-6-13-02,
above. This peak list was searched in MASCOT, which identified it as actin with a score of 107.

1130.324
1198.524
1483.336
1501.456
1727.517
1790.530
1955.621
1975.544
2227.686
3196.114

Figure 50: Tryptic digest spectra and generated peak list of excised protein band 2P from the gel 1D-6-13-02,
above. This peak list was searched in MASCOT, which identified it as tropomyosin with a score of 81.

MASCOT Search Results
Gel

Protein Identification
Band

MASCOT

Sequence

Mass

Score

coverage

(kDa)

pI

1D-6-13-02

1C

Tropomyosin

63

52%

~33

4.6

1D-6-13-02

2C

Actin

107

73%

~42

5.2

1D-6-13-02

2P

Actin

81

59%

~42

5.2

Table 4: List of the MASCOT search results for protein bands digested with trypsin from the 1D gel 6_18_02.
Digest mixtures were analyzed with MALDI-TOF MS and searched in a protein database using the MASCOT
search engine.

IPG strips, which allow an upper limit of 1 mg of protein dissolved in 1 mL of buffer,
were then used for IEF separation to improve protein band intensities. The 2D gels obtained
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from this technique were considerably more concentrated, and could be stained with Coomassie
Brilliant Blue stain (Figures 49-50).
2D_9_26_03_Control

Figure 51: Example of a 2D gel containing membrane proteins from resting aortic SM tissue solubilized
with boiling in 10% SDS, and later purified via acetone precipitation. The protein quantity in the bands of this gel
was high enough to be visualized by Coomassie Brillaint Blue staining.
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2D_9_26_03_Phorbol

Figure 52: Example of a 2D gel containing membrane proteins from phorbol-contracted aortic SM tissue
solubilized with boiling in 10% SDS, and later purified via acetone precipitation. The protein quantity in the bands
of this gel was high enough to be visualized by Coomassie Brillaint Blue staining.

It has also been observed that few low molecular weight proteins exist on the 2D gels.
This may be because low MW proteins either migrated off the 2nd dimension slab gel due to
over-extended running times or because they migrated out of the tube gel during equilibration of
the tube gels in methylene blue. The second explanation is more likely, because it is not
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believed that the second dimension separation time was too long. Applied voltages were stopped
before the line of methlyene blue dye migrated off the gel, after approximately 4.5 to 5.0 hours.
The MW of methylene blue is 319.85 Da, much smaller than the MW of proteins expected to be
in biological samples.
Once a gel of adequate protein level—that able to be detected by Coomassie staining—
was produced, then phosphoprotein detection and protein identification through MS analysis
could be conducted. In the future, it is recommended that a Bradford Protein Assay—to
determine the concentration of protein—be conducted prior to electrophoresis to assure that
equal amounts of total protein from the contracted and uncontracted tissue are used.
MALDI-TOF MS Analysis
Low S/N ratios of peaks made MS analysis difficult. Such poor quality spectra are partly
explained by the low concentration of protein on the gels produced for tube gel IEF separation.
Examples of such spectra may be seen in figures 32-46, above. Once the problem of low protein
abundance in gel plugs was solved by using IPG strips in the 1st dimension separation of 2D
SDS-PAGE, another problem was discovered in MS analysis. The instrument did not appear to
hold calibration. M/z values shifted irregularly over time. MS spectra provided by the
instrument used in this research proved to be ambiguous and not reproducible, which would
largely explain the lack of sufficient results. Parameters for the LASER attenuation and
extraction voltages were not changed, and are not the source of ambiguity.
Equilibration of the acceleration voltage, delayed extraction voltages, and/or reflectron
voltages was targeted as an initial source of error. Deviation in these voltages from the set
voltage will result in deviant computations of m/z (see Appendix I). The voltages were checked
with a voltmeter and did not deviate from the set values. However, approximately 15 minutes
was allowed for equilibration of the high voltages prior to acquisition of data. This did not solve
the problem.
Improportional depth of the target probe has also been proposed as a source of error.
Slight deviations in the depth of analyte within the ionization chamber can cause differences in
the distance traveled by the ions, and subsequent deviations in computed m/z values. Methods to
combat inhomogeneity on the surface of the probe, such as the two-layer method of spotting,
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were always applied. In this method, a homogenous layer of matrix is spotted using a volatile
solvent, and the matrix-embedded sample is spotted on top of this layer to create a homogenous
surface layer of analyte. The purchase of a new probe may also aid in this problem. It is
possible that the probe may have been damaged due to mishandling and may not be even. This
has not yet been tried.
The application of an internal standard was then utilized to combat this problem, with
limited success. For this application a diluted extract of peptide standards was added to a
fraction of the sample mixture, which was then spotted on the MALDI probe. The acquired
spectrum containing the internal standards was calibrated. Abundant sample peptide peaks were
chosen as calibrants for the spectrum containing only peaks from the sample mixture—no
internal standards. Using this methodology, the localization of some proteins on the 2D gel were
discovered, including actin, tropomyosin, and MHC. The data supporting these conclusions may
be seen in figures 53-63 and table 5, below.
649.913
894.093
898.100
904.041
906.076
926.039
931.105
948.075
985.104
989.049
1000.089
1009.969
1015.017
1031.402
1046.076
1058.086
1062.061
1068.045
1070.055
1073.085
1084.030
1088.084
1099.981
1103.062
1107.981
1108.994

1131.034
1133.994
1140.043
1165.038
1179.046
1182.017
1186.127
1218.006
1226.121
1233.026
1243.082
1253.923
1262.058
1265.013
1314.165
1364.996
1399.016

Figure 53: Tryptic digest spectra and generated peak list of excised protein band 1C from the gel
2D_10_9_02_Control. This peak list was searched in MASCOT, which identified it as tropomyosin with a score of
278.
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901.340
918.534
928.499
944.445
1046.819
1074.758
1166.404
1171.551
1183.416
1187.508
1244.280
1299.359
1327.188
1333.145
1344.153
1357.130
1366.109
1406.135
1791.883
2365.341
2385.146
2401.757

Figure 54: Tryptic digest spectra and generated peak list of excised protein band 4C from the gel
2D_10_9_02_Control. This peak list was searched in MASCOT, which identified it as tropomyosin with a score of
88.
896.550
901.641
918.800
925.763
929.777
944.767
1047.886
1061.322
1067.300
1074.841
1083.165
1127.739
1130.615
1136.466
1150.507
1166.476
1171.613
1183.398
1186.359
1244.406
1299.366
1302.140

1309.250
1327.196
1333.207
1344.155
1349.198
1357.137
1365.214
1389.046
1400.158
1406.127
1461.077
1476.228
1489.027
1632.116
1723.055
1791.904
2222.172
2239.150
2365.364
2384.032
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Figure 55: Tryptic digest spectra and generated peak list of excised protein band 6C from the gel
2D_10_09_02_Control. This peak list was searched in MASCOT, which identified it as tropomyosin with a score
of 112.
795.385
800.414
860.973
945.404
967.393
973.404
976.335
998.336
1036.302
1045.382
1130.391
1161.415
1171.400
1187.432
1198.450
1475.451
1483.400
1499.390
1500.418

1516.469
1765.387
1790.660
1812.587
1935.832
1953.693
1955.638
1977.691
2227.668
2235.648
2243.647
2296.531
2306.857
2350.035
2506.057
2565.747
2724.929

Figure 57: Tryptic digest spectra and generated peak list of excised protein band 8C from the gel
2D_10_09_02_Control. This peak list was searched in MASCOT, which identified it as actin with a score of 108.
920.324
974.206
975.274
1036.816
1046.820
1049.818
1066.734
1090.633
1107.614
1122.622
1135.490
1141.479
1165.432
1179.423
1184.392
1194.396
1201.426
1203.330
1206.344
1222.311
1223.462
1234.342

1241.279
1244.351
1259.189
1265.274
1277.248
1300.071
1307.194
1316.213
1365.089
1366.149
1379.170
1383.087
1391.138
1407.102
1427.195
1431.133
1434.144
1458.091
1475.101
1487.100
1493.016

Figure 58: Tryptic digest spectra and generated peak list of excised protein band 12C from the gel
2D_10_09_02_Control. This peak list was searched in MASCOT, which identified it as MHC with a score of 86.
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1471.326

1072.402
1476.287
1084.502
1489.633
1100.488
1504.340
1109.522
1547.740
1129.522
1587.497
1133.490
1603.617
1140.726
1605.708
1146.560
1699.747
1157.685
1178.634
1185.729
1197.721
1213.771
1242.830
1256.993
1270.908
1280.738
1299.938
1314.020
1342.082
1373.339
1404.079
1431.467
1458.219

Figure 59: Tryptic digest spectra and generated peak list of excised protein band 11P from the gel
2D_7_30_02_Phorbol. This peak list was searched in MASCOT, which identified it as tropomyosin with a score of
74.
856.228
876.077
892.011
975.676
1045.051
1130.303
1140.388
1150.377
1162.395
1171.418
1183.901
1198.622
1260.795
1330.998
1355.094
1501.716
1537.064
1631.296
1793.136
1807.238
1815.118
1821.309
1855.415
1862.517

2215.275
2229.358
2232.355
2248.528
2389.008
2512.835
2528.920
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1879.648
1883.679
1957.012
1959.006
1987.086

Figure 60: Tryptic digest spectra and generated peak list of excised protein band 1C from the gel 2D_7_12_02
_Control. This
peak list was
searched in
MASCOT, which
identified it as
tropomyosin with
a score of 59.
1045.136
1065.838
1081.691
1097.643
1150.498
1197.721
1201.743
1267.993
1299.093
1490.064
1537.327
1730.038
1758.119
1792.239
1802.430
1820.334
1886.805
1949.033
2206.461
2215.500
2229.623
2280.740
2287.946
2524.225
2548.429

Figure 61: Tryptic digest spectra and generated peak list of excised protein band 5P from the gel 2D_7_12_02
_Phorbol. This peak list was searched in MASCOT, which identified it as MHC with a score of 61.

MASCOT Search Results
Gel

Protein

Identification

MASCOT

Sequence

Mass

pI
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Band

Score

coverage

(kDa)

10_09_02_Control

1C

Tropomyosin

278

73%

~33

4.6

10_09_02_Control

4C

Tropomyosin

88

47%

~33

4.6

10_09_02_Control

6C

Tropomyosin

112

43%

~33

4.6

10_09_02_Control

8C

Actin

108

45%

~42

5.2

10_09_02_Control

12C

MHC

86

44%

--

10_09_02_Phorbol

11P

Tropomyosin

74

40%

~150250
~33

4.6

7_12_02_Control

1C

Tropomyosin

59

34%

~33

4.6

7_12_02_Phorbol

5P

MHC

61

56%

~150250

--

Table 5: List of the MASCOT search results for protein bands digested with trypsin that were successfully
identified with the aid of internal standards from various gels (as designated in the figures, above). Digest mixtures
were analyzed with MALDI-TOF MS and searched in a protein database using the MASCOT search engine.

The acquisition of quality spectra for both the sample spot and the sample with standards
spot was difficult, given the already low S/N ratios of peaks. The same problem of low protein
quantity described before contributed to the lack of adequate spectra. This trend hindered the
ability to calibrate the spectra using this method.
The application of an internal standard within sample mixtures helped to demonstrate
the inconsistencies encountered during operation of the MALDI-TOF instrument. The following
spectra were acquired chronologically as they are listed in the text. The correct m/z values for
the internal standards used are listed in table 2. The shift in the reported m/z values
corresponding to these standards can be seen in the spectra, below.
The first three spectra are from the same sample spot (Figures 62-64). The standard
peaks first shift down in m/z and then shift back up without changing any parameters, though the
position on the spot where the LASER was fired was changed.
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Figure 62: Tryptic digest from band 10P from the gel 2D_9_26_03_Phorbol. The uncalibrated m/z peaks for the
standards substance P, bombesin, and ACTH clip 18-39 can be seen. When compared to the other spectra of this
same spot (Figures 61 and 62), the shifts in the m/z values can be seen.

Figure 63: Tryptic digest from band 10P from the gel 2D_9_26_03_Phorbol. The uncalibrated m/z peaks for the
standards substance P, bombesin, and ACTH clip 18-39 can be seen. When compared to the other spectra of this
same spot (Figures 60 and 62), the shifts in the m/z values can be seen.
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Figure 64: Tryptic digest from band 10P from the gel 2D_9_26_03_Phorbol. The uncalibrated m/z peaks for the
standards substance P, bombesin, and ACTH clip 18-39 can be seen. When compared to the other spectra of this
same spot (Figures 60 and 62), the shifts in the m/z values can be seen.

The following four spectra all contain standard peaks (Figures 65-68). They are from different
sample spots acquired on the same day, listed chronologically in time. Again, none of the
parameters of the instrument were changed. The ambiguity of the m/z values reported for the
standard peaks can be seen.
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Figure 65: Tryptic digest from band 1P from the gel 2D_9_26_03_Phorbol. The uncalibrated m/z peaks for the
standards substance P, bombesin, ACTH clip 18-39, and Somatostatin-28 can be seen. When compared to the other
spectra acquired on the same day under the same instrumental parameters (Figures 65-68), the shifts in the m/z
values can be seen.

Figure 66: Tryptic digest from band 4P from the gel 2D_9_26_03_Phorbol. The uncalibrated m/z peaks for the
standards substance P, bombesin, ACTH clip 18-39, and Somatostatin-28 can be seen. When compared to the other
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spectra acquired on the same day under the same instrumental parameters (Figures 65,67-68), the shifts in the m/z
values can be seen.

Figure 67: Tryptic digest from band 6P from the gel 2D_9_26_03_Phorbol. The uncalibrated m/z peaks for the
standards substance P, bombesin, ACTH clip 18-39, and Somatostatin-28 can be seen. When compared to the other
spectra acquired on the same day under the same instrumental parameters (Figures 65-66, 68), the shifts in the m/z
values can be seen.
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Figure 68: Tryptic digest from band 2P from the gel 2D_9_26_03_Phorbol. The uncalibrated m/z peaks for the
standards substance P, bombesin, ACTH clip 18-39, and Somatostatin-28 can be seen. When compared to the other
spectra acquired on the same day under the same instrumental parameters (Figures 65-67), the shifts in the m/z
values can be seen.

Many adequate digest spectra, with a sufficient number of suitable S/N ratio peaks, were
produced that could not be identified when peak lists were searched in the protein database.
Some of these spectra can be seen in figures 69-74. Unfortunately, many protein candidates
were found for each peptide fingerprint entered into the protein database search. Different
search engines were used to determine whether the search engine was to blame for the lack of
results. The same ambiguous results were furnished by the search engines. No two search
engines produced the same results, either.
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Figure 69: Example of a tryptic digest of band 14C from the gel 2D_7_30_02_Control. The spectrum has a
sufficient number of adequate S/N peaks, but no identification could be made in the protein database.

Figure 70: Example of a tryptic digest of band 11P from the gel 2D_7_30_02_Phorbol. The spectrum has a
sufficient number of adequate S/N peaks, but no identification could be made in the protein database.
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Figure 71: Example of a tryptic digest of band 16C from the gel 2D_10_09_02_Control. The spectrum
has a sufficient number of adequate S/N peaks, but no identification could be made in the protein database. This
spectrum was calibrated with internal standards, as well.

Figure 72: Example of a tryptic digest of band 26C from the gel 2D_10_09_02_Control. The spectrum
has a sufficient number of adequate S/N peaks, but no identification could be made in the protein database.
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Figure 73: Example of a tryptic digest of band 9CP from the gel 2D_10_09_02_Control_Pell. The
spectrum has a sufficient number of adequate S/N peaks, but no identification could be made in the protein
database.

Figure 74: Example of a tryptic digest of band 17C from the gel 2D_10_09_02_Control. The spectrum
has a sufficient number of adequate S/N peaks, but no identification could be made in the protein database.
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A sufficient explanation as to why the instrument provides irregularly shifted m/z values
has yet to be determined. Unintentional venting of the vacuum chambers may have allowed
accumulation of water vapor, gases, dust, or other contaminants that would collide/interfere with
the propogation of ions down the flight tube. Normal internal corrosion of the elements within
the instrument due to the presence of such contaminants would also affect the performance of the
instrument. The internal components should be thoroughly cleaned with a volatile solvent, such
as methanol, to combat this problem. Software discrepancies may also contribute to the
irregularity of generated data, in the computation of m/z values or the production of spectra, but
it is difficult to pinpoint this as a problem unless the entire software were replaced, and data
generated from the new software is tested.
In the cases where no identifications were made for digest spectra of good quality, it is
always possible that the proteins were as yet uncharacterized/unidentified proteins, not in the
database. However, this is unlikely, because the protein bands chosen were intense, they should
be highly abundant and identified proteins in SM tissue.
In many digest spectra, what appeared to be contaminating polymer peaks were observed
(Figures 75- 78). An experimental blank tryptic digest was performed on a small quantity of the
latex gloves used regularly in the laboratory. The resultant spectrum is shown in figure 80. This
may explain the source of the contaminating polymer peaks
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Figure 75: Tryptic digest averaged spectrum of protein band 6C from the 2D gel 2D_7_30_02_Control, revealing
contaminating polymer peaks.

Figure 76: Tryptic digest averaged spectrum of protein band 1C from the 2D gel 2D_7_30_02_Control, revealing
contaminating polymer peaks.
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Figure 77: Tryptic digest averaged spectrum of protein band 23C from the 2D gel 2D_10_09_02_Control,
revealing contaminating polymer peaks.

Figure78: Tryptic digest averaged spectrum of obtained when trypsin was added to a piece of the latex glove used
in the laboratory, The spectrum reveals polymer peaks similar to those seen as contamination in many of the sample
spectra, and may explain the source of such contamination.
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Some observed phenomenon have yet to be explained. The modified and purified trypsin
enzyme used for this analysis was purchased from Sigma-Aldrich. The trypsin was reportedly
modified by dimethylation of lysine residues to prevent autolysis. The m/z peaks that would be
obtained form autolysis of the modified trypsin are listed in table 6. An experimental blank was
performed in which the trypsin was incubated with a blank piece of gel in attempt to allow
autolysis. The spectra and peak list obtained from this blank may be seen in Figure 79 and Table
7, below.
The two sets of peaks for the theoretical and the experimental are incongruent with each
other. The explanation for this is not known. It is suggested that the Sigma-Aldrich trypsin is
modified in a different way or that instrument was malfunctioning as discussed earlier to produce
m/z peaks of inaccurate value. The experimental blank was used to identify contaminating
trypsin peaks in sample spectra.

1045.811
1109.803
1158.915
1186.905
1192.941
1236.931
1344.150
1388.186
1432.334
1448.133
1476.169
1492.146
1503.106
1517.081
1606.148
1622.192
1628.224
1635.198
1740.406

1744.266
1849.249
1888.293
1893.404
2048.456
2055.453
2067.366
2209.504
2224.469
2237.546
2351.598
2510.736
2633.923

Table 6: List of m/z peaks obtained from a theoretical digest of dimethylated trypsin.
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Figure 79: Averaged digest spectrum of self-digested, dimethlyated trypsin purchased from Sigma-Aldrich
performed in the laboratory at Marshall University to be referenced as an experimental blank for identification of
contaminating trypsin peaks in sample spectra.

805.41
906.51
934.54
962.57
1020.20
1046.60
1048.54
1048.54
1074.63
1111.56
1139.57
1181.61
1364.69
1392.72
1420.75
1433.72
1461.75
1495.61
1497.76
1523.64

1999.04
2027.08
2055.11
2083.14
2163.05
2191.08
2193.99
2209.98
2238.02
2273.16
2289.15
2301.19
2317.18
2321.20
2349.23
2377.27
2405.30
2514.33
2530.33
2542.37

2580.28
2586.39
2803.42
2831.45
2910.31
2938.35
2966.38
3195.48
3211.47
3223.51
3239.50
3251.54
3267.53
3338.64
3366.67
3670.59
3686.58
3686.80
3698.62
3714.61
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1525.79
1725.87
1753.89

2552.24
2558.36
2570.40

3714.83
3726.65
3742.64

Table 7: List of m/z peaks obtained from experimental autolysis of the dimethylated trypsin purchased from
Sigma-Aldrich. These peaks are incongruent with those expected from the theoretical digest in table 5.

In many digest spectra, trypsin peaks were evident. This may be due to a concentration
of trypsin that was too high for the amount of protein. Either the quantity of protein in the
digested band was too low, as was often the case when the gels had to be silver stained, or too
much trypsin was added. The abundance of trypsin peaks present in a sample spectrum could
conceivably suppress actual peptide peaks, making protein identification and other analysis more
difficult.
PSD Analysis
It was hoped that the employment of post source decay (PSD) analysis of peptide
fragments within digested spectra would help facilitate a more positive identification of putative
proteins. However, a good PSD spectrum was never obtained using the techniques described in
this research. Preliminary spectra obtained in the acquisition of data during the stepwise voltage
acclamations were of very poor resolution, especially those obtained from low reflector voltages
which would deflect those fragments of lower MW. Naturally, if these are of poor quality, the
subsequent fragmentation spectrum constructed from them will be of equally poor quality.
Manipulation of lens voltages to improve resolution of peaks proved unsuccessful.
Because a good standard PSD fragmentation spectrum was never obtained, calibration of the
instrument could not be performed, much less PSD analysis for an unknown sample spectrum.
The instrumental software’s peak picking parameters were found to be inadequate for choosing
real m/z peaks, or else the calibration file was inaccurate. The m/z peaks chosen by the software
were not real peaks, but noise spikes. Definite m/z peaks, though of poor resolution, were
ignored by the software. It is probable that the ion gate that functions to preselect the peptide to
be fragmented from the mixture of analytes was not working properly. This would inevitably
cause difficulties in obtaining sufficient PSD data for sequencing the peptide.
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MASCOT Search Results
Unfortunately, many protein candidates were found for each peptide fingerprint entered
into the protein database search—too many to report at full length in this collection.
An example of the possible candidates for one such spectra—band 1P from the 2D gel
7_12_02_phorbol_sup—is reported here (Figure 80). First, a list of the possible candidates was
obtained from the MASCOT search engine, allowing for the indicated variable modifications.
These candidates are listed in table 8, below.

Figure 80: Tryptic digest spectra band 1P after from the 2D gel 2D_7_12_02_Phorbol. The peak list from this
spectra was searched in the protein database by MASCOT to determine its identification.

Possible IDs of Band 1P
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Possible

# of

MASCOT

Sequence

Candidates

Matching

Score

coverage

Mass (Da)

Variable
Modifications

Peaks
α-actinin

30

28

48%

105176

Oxidized Met

Filamin C

29

42

34%

119496

Oxidized Met

Plectin 1

32

30

43%

95964

Oxidized Met

Vimentin

28

35

57%

53623

Oxidized Met

Vinculin

38

28

41%

117171

Oxidized Met

Integrin-

31

27

56%

51827

Oxidized Met
Phos. Thr/Ser

linked PK
PKA

26

25

47%

30322

Oxidized Met
Phos. Thr/Ser

Table 8: List of the possible candidates for the identity of band 1P from the 2D gel 7_12_02_phorbol_sup.

Much information can be interpreted using the information in the database, and
comparisons can be made between the characteristics of likely candidates and the experimentally
determined parameters of a given protein digest, such as MW and pI. If these parameters do not
match that of the unknown, it can be eliminated as a candidate. The protein α-actinin is used as
an example to show the comparison. In figure 81, the sequence of the protein covered by the
peptide fingerprint spectra is shown. Table 9 compares the matching peaks in the sample spectra
to the peptide fingerprint of the protein, α-actinin.
1 MVMEKPSPLL VGREFVRQYY TLLNQAPDML HRFYGKNSSY AHGGLDSNGK
51 PADAVYGQKE IHRKVMSQNF TNCHTKIRHV DAHATLNDGV VQVMGLLSN
101 NNQALRRFMQ TFVLAPEGSV ANKFYVHNDI FRYQDEVFGG FVTEPQEESE
151 EEVEEPEERQ QTPEVVPDDS GTFYDQTVSN DLEEHLEEPV VEPEPEPEPE
201 PEPEPVSDIQ EDKPEAALEE AAPDDVQKST SPAPADVAPA QEDLRTFSWA
251 SVTSKNLPPS GAVPVTGTPP HVVKVPASQP RPESKPDSQI PPQRPQRDQR
301 VREQRINIPP QRGPRPIREA GEPGDVEPRR MVRHPDSHQL FIGNLPHEVD
351 KSELKDFFQN FGNVVELRIN SGGKLPNFGF VVFDDSEPVQ KVLSNRPIMF
401 RGAVRLNVEE KKTRAAREGD RRDNRLRGPG GPRGGPSGGM GPPRGGMVQ
451 KPGFGVGRGI TTPRQ
Figure 81: Sequence coverage of the peptides matched for the band 1P from the 2D gel 7_12_02_phorbol_sup to
α-actinin, obtained from the MASCOT database search. Matching peptides are shown in red.

1P
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Amino acid
Start - End

Observed
M+ Ion

Mass
(expt) (Da)

Mass
(calc) (Da)

Deviation
(Da)

41 - 50
51 - 65
54 - 66
66 - 83

1201.85
1934.23
1647.73
2047.83

1200.84
1933.22
1646.72
2046.82

1198.62
1931.95
1647.83
2048.02

2.22
1.27
-1.11
-1.19

# of
Missed
Cleavages
0
2
2
2

Amino acid Sequence

DLLLDPAWEK
QQRKTFTAWCNSHLR
KTFTAWCNSHLRK
KAGTQIENIDEDFRDGL
K
80 - 101
2524.39
2523.38
2521.43
1.95
2
DGLKLMLLLEVISGERL
PKPER Oxidation (M)
109 - 125
1830.77
1829.76
1830.04
-0.27
2
INNVNKALDFIASKGVK
115 - 125
1150.06
1149.06
1147.66
1.40
1
ALDFIASKGVK
182 - 214
3974.08
3973.07
3973.05
0.02
2
NVNVQNFHISWKDGLA
FNALIHRHRPELIEYDK
205 - 214
1299.32
1298.31
1298.66
-0.35
0
HRPELIEYDK
218 - 233
1776.38
1775.37
1774.84
0.54
0
DDPVTNLNNAFEVAEK
234 - 255
2533.84
2532.83
2531.26
1.58
1
YLDIPKMLDAEDIVNTG
RPDEK
234 - 255
2548.56
2547.55
2547.25
0.30
1
YLDIPKMLDAEDIVNTG
RPDEK Oxidation (M)
240 - 255
1802.60
1801.59
1801.85
-0.26
0
MLDAEDIVNTGRPDEK
256 - 283
3120.72
3119.71
3121.51
-1.80
2
AIMTYVSSFYHAFSGAQ
KAETAANRICK
312 - 331
2485.06
2484.05
2483.28
0.77
2
TIPWLEDRVPQKTIQEM
QQK Oxidation (M)
332 - 340
1272.09
1271.08
1268.63
2.46
2
LEDFRDYRR
364 - 378
1730.18
1729.18
1729.90
-0.72
1
LRLSNRPAFMPSEGR
396 - 410
1915.20
1914.19
1915.98
-1.79
1
GYEEWLLNEIPRLER
451 - 469
2206.65
2205.64
2206.12
-0.48
2
ALIRKHEAFESDLAAHQ
DR
519 - 536
2215.74
2214.73
2214.16
0.57
2
TEKQLETIDQLHLEYAK
R
605 - 632
3141.80
3140.79
3140.69
0.11
2
LSGSNPYTSVTPQIINSK
WEKVQQLVPK
633 - 643
1327.51
1326.50
1324.67
1.83
1
RDHALLEEQSK
634 - 643
1171.73
1170.72
1168.57
2.15
0
DHALLEEQSK
653 - 668
1820.56
1819.55
1820.89
-1.34
0
QFASQANMVGPWIQTK
Oxidation (M)
761 - 779
2314.84
2313.83
2314.04
-0.21
1
GISQEQMQEFRASFNHF
DK Oxidation (M)
780 - 813
3764.53
3763.52
3764.71
-1.19
2
DHGGALGPEEFKGCLIS
LGYDVENDRQGDAEFN
R
814 - 837
2682.21
2681.20
2682.32
-1.12
0
IMSVVDPNHSGLVTFQA
FIDFMSK
854 - 868
1706.05
1705.04
1702.93
2.12
1
VLAGDKNFITVEELR
869 - 882
1689.00
1687.99
1688.82
-0.83
1
KELPPDQAEYCIAR
900 - 911
1291.10
1290.09
1288.58
1.51
0
SFSTALYGESDL
Table 9: List of the matching monoisotopic m/z peaks of the sample band 1P from the 2D
gel7_12_02_phorbol_sup compared to those of the candidate α-actinin.
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Variable phosphorylation of serine and threonine residues can also be tested in the
database search. However, this comparison allows all possible serine and threonine residues to
be phosphorylated, when matching theoretical peak masses. Phosphorylation at so many
residues at once, or at all, is not likely. That makes this option of identifying phosphorylation
sites tedious and most likely inaccurate. This option also provides more possible candidates for
identification.
Only those candidates with significant MASCOT scores (>62) have been reported in
depth. It was decided that a definitive positive identification should be concluded before time is
spent, and likely wasted, investigating every possibility. Often, many likely candidates were
produced with comparable, though insignificant, scores. There is simply not enough evidence to
choose one candidate over another. The successfully identified proteins have been discussed,
previously.
Only the MASCOT score, percentage of sequence coverage, and number of matched m/z
peaks for each candidate are reported here. Of course, some spectra were very poor and did not
have enough peaks to make any kind of characterization possible. Spectra with fewer than 8
peaks were not searched in the MASCOT database.
Unmatched Peaks
1143.59

1792.38

1309.17

1841.76

1313.44

1871.28

1444.90

1886.98

1489.97

1901.13

1551.34

1984.40

1596.36

2220.76

1618.66

2234.84

1715.49

2476.17

1722.11

2540.46

1758.34

2576.72

Table 10: List of the unmatched monoisotopic m/z peaks of the sample band 1P from the 2D gel
7_12_02_phorbol_sup when compared to the m/z peaks of α-actinin.
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Unmatched peaks may be molecules with salt adherents—such as sodium (Na+) or
potassium (K+)—, matrix peaks, trypsin peaks, or modified peaks (phosphorylated, glycosylated,
etc). There is always the possibility that an incorrect identification has been made by the search
engine. This probability is too high for candidates with MASCOT scores below the level of
significance. Unmatched peaks may even be part of a second protein that migrated to a position
on the gel near the band of interest, thus contaminating the sample analyte. Though this does not
occur very often given the size of normal 2D gels.
Despite the limitations afforded by poor spectra, some general conclusions can be drawn
from the lists of possible candidates. For example, it appears that the protein of band 1P, above,
is at least a structural or filamentous protein involved in the cytoskeleton, because the majority
of the likely candidates are structural proteins found in muscle tissue. The most rational options
would be either vimentin or α-actinin—structural proteins already known to exist in SM tissue.
However, the possibility that the protein is an unknown structural protein still remains and
cannot be ruled out.
Similar results were found for most of the protein spectra analyzed. Unfortunately, poor
spectra prevented a positive identification for most of the spectra analyzed. Low MASCOT
scores and a broad range of putative proteins inhibited any successful characterization. Such
problems encountered in the development of this research have slowed its progress.

Phosphoproteomic Analysis
Phosphoproteomic analysis was difficult given the methods use thus far and
incorporating the setbacks imposed by encountered difficulties with the protocol. Sample
enrichment, β-elmination, and other specific phosphoproteomic techniques have yet to be
conducted, and should be attempted in the future. As mentioned in the introduction, analysis of
phosphoproteins/peptides is more difficult because of their low stochiometric abundance in
digested peptide mixtures. Sample enrichment should improve their selective abundance.
Phosphopeptides are also very hydrophilic and will not be selectively detained using the standard
reverse-phase chromatography techniques used in this investigation. Purification of enriched
sample using OligoR3 columns should instead by conducted in future work.
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Two methods of detecting phosphorylated proteins were attempted in this research. The
first utilized radioactive phosphorous-33 (33P) enrichment of tissue extracts coupled with
autoradiographic detection to assay differential phosphorylation of proteins separated on 2D
gels. This method was only attempted once with limited success. The autoradiographs produced
from this protocol are shown in figures 82-85.

Autoradiograph Control

Figure 82: Autoradiograph obtained from a 2D gel produced from tube gel IEF separation with 12 hours of
exposure. Aqueous proteins from resting SM tissue were used. The radiograph reveals no phosphorylated bands.

Autoradiograph Phorbol
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Figure 83: Autoradiograph obtained from a 2D gel produced from tube gel IEF separation with 12 hours of
exposure. Aqueous proteins from phorbol-contracted SM tissue were used. The radiograph reveals
phosphorylation on the band corresponding to tropomyosin.

Autoradiograph Phorbol

Figure 84: Autoradiograph obtained from a 2D gel produced from tube gel IEF separation with 36 hours of
exposure. Aqueous proteins from phorbol-contracted SM tissue were used. More evidence of phosphorylated
bands can be seen.

Autoradiograph Phorbol-Membrane Proteins
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Figure 85: Autoradiograph obtained from a 2D gel produced from tube gel IEF separation with 36 hours of
exposure. SDS-solubillized proteins from phorbol-contracted SM tissue were used. More evidence of
phosphorylated bands can be seen.

For the first trial, evidence of phosphorylated proteins can be seen only for the protein
band corresponding to tropomyosin on the phorbol-contracted gels (Figure 82). So, it can be
concluded that the level of phosphorylation of tropomyosin increases during contraction. The
enzyme that phosphorylates/dephosphorylates this protein is not known. This method was used
in conjunction with tube gel IEF focusing. For this reason, the quantity of protein on the gel
available for detection and subsequent analysis is low, as expected. The gels had to be silver
stained to visualize any protein bands. This may explain the lack of evidence of phosphorylated
proteins on the gel.
For the second trial, only gels corresponding to phorbol-contracted tissue were obtained.
The corresponding silver stained gels can be seen in figures 32 and 46, respectively. These
autoradioagraphs were subjected to a longer exposure time, so that phosphoprotein bands were
more intense and better visualized. However, due to the lack of a corresponding control gel for
resting tissue, differential analysis could not be conducted at this point. No protein
identifications were made from these gels for the reasons discussed previously. Mainly, low
protein concentration in the bands visualized by silver staining made analysis difficult, and thus
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far, unsuccessful. Therefore, the identity of the phosphoproteins visualized on these gels is not
known. However, improvement in this area promises better analysis for the future.
The second method for visualizing phosphoproteins makes use of the phosphospecific
stain from Molecular Probes—ProQ Diamond Phosphoprotein stain, which binds more tightly to
phosphorylated proteins than nonphosphorylated proteins due to charge interactions between the
negatively-charged phosphate groups and the positively-charged stain molecules.
No bands were ever visualized using this stain, despite attempted modifications of
lengthened staining and destaining periods. This method was attempted only in connection with
the gels produced from IPG strips, so the total protein concentration should be high enough for
detection. It is possible that the light source and camera used to excite and detect the stain were
insufficient. The appropriate camera and filters may greatly enhance the sensitivity of the stain.
These resources were not available. It is also possible that the stain is simply not sensitive
enough to bind to and detect the low abundant phosphoproteins in biological samples.
Interference between the stain and free phosphate groups can occur if tissues are
incubated in phosphate buffers. No such buffers were used during the lysis procedure conducted
in preparation of the sample. Protein extracts should also be sufficiently purified during the
acetone precipitation.
Because phosphoproteins were not sufficiently detected using the phosphoprotein stain,
gels were stained with a total protein stain to look for deviations in the intensity of
corresponding bands between the contracted and uncontracted gels. However, identification of
proteins was not achieved, as was discussed earlier.

CONCLUSIONS
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Though some identifications of proteins in SM have been made given the results, thus
far. Unexpected setbacks and other protocol adaptations have slowed research. So far, the
localization of actin, tropomyosin, and MHC on a 2D gel has been discovered. It has also been
concluded that tropomyosin is phosphorylated during contraction. As tropomyosin and actin
bands can be seen in almost every gel, it may be concluded that they are present in abundance
within aortic SM tissue. The heavy phosophorylation of this abundant protein implicate that this
protein may play a larger role in contractile regulation than originally thought.
The primary objective of this research focused on the differential phosphorylation
analysis between contracted and resting aortic SM tissue in order to better understand the
mechanisms of signal transduction. Instead, the body of this work focused on the development
of protocol for the analysis of phosphoproteins. Many problems were identified and solved.
However, the largest obstacle of acquiring accurate, reproducible MS data to facilitate
identification of proteins using the protein database still remains.
Future work in this investigation should include a Bradford assay for protein quantitation,
use of the IPG strips for IEF separation of proteins to improve protein concentration on the 2D
slab gels, and the use of phosphoproteomic techniques (sample enrichment of phosphoproteins,
phosphatase inhibitors in cell lysis, ß-elimination, Michael addition, etc.) for the selective
analysis of phosphoproeins. Analysis of differential glycosylation in control and contracted SM
tissue may be of interest for the future, as well.
Once a suitable protocol has been developed, the use of proteomic analysis should
provide valuable information concerning the phosphorylation state of proteins in SM due to
contraction, and from this information, conclusions made be drawn about signal transduction
behind it. Once such goals have been accomplished, it should be followed by the use of different
states of contraction (tonic/phasic), time dependent exposure of tissue to agonist, the effects of
different agonists and/or relaxants on the state of phosphorylation, and perhaps different SM
tissues. Ofcourse, analysis of signaling cascades in dysfunctional SM tissue should be explored,
as well. There are many avenues of exploration that may be pursued, both biochemical at the
molecular level and biophysical at the macroscopic level—mechanics/dynamics of contraction.
These preliminary results are just a small step in the process of understanding SM
contraction. The need for its understanding becomes evident when the dominant and ever110

expanding threat of cardiovascular disease—the second leading cause of death in the United
States, and number one in many countries (AHA 2002)—is considered. A thorough
understanding of contraction in normal tissue will provide the base for which dysfunctions can
be compared. Drug therapy, in particular, calls for the development of new, improved relaxants
for the treatment of hypertension. Vascular SM contraction may also play a role in the
development of atherosclerosis, which may be treated within SM tissue. Improvements in
phosphoproteomic techniques and instrumentation capabilities will aid in the conquest.

APPENDIX I:
Mass Spectrometry
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The general principle behind mass spectrometry (MS) is the separation of gas phase ions
based on their molecular weight (MW), or more specifically, the ratio of their mass to charge
(m/z). The advanced technology and specialization of mass spectrometry instrumentation and
applications grows increasingly complex and sophisticated. Therefore, this appendix will cover
only the general characteristics of MS.
The instrumentation of a mass spectrometer operates under three basic components: the
source, the mass analyzer, and the detector. The choice of which type of each component is used
depends on their suitability to the most desired qualities for sample analysis.
The source serves to vaporize and ionize—supple an electrical charge to—the sample
analyte. Several different methods of ionization have evolved through avid research. In general,
the ionization technique must transfer enough energy to the sample to cause it to vaporize.
In electron ionization (IE), the sample is bombarded with thermionic emission from a
tungsten or rhenium filament (typically 70 eV). Fast atom bombardment (FAB) blasts a matrixembedded sample with a fast beam of particles—usually an inert gas (Ar/Xe)—to facilitate
ionization. Similarly, liquid secondary ion mass spectrometry (LSI-MS) uses an ion (usually
CS+) to ionize the sample.
In electrospray ionization (ESI) makes use of the phenomenon of charged droplet
evaporation. The sample solution is forced through a capillary to cause spraying or bubbling,
producing minuscule charged droplets. A potential is then used to disperse the droplet into a fine
spray of smaller droplets. The solvent evaporates away, shrinking the droplet, and causing the
charged ions to get closer and closer together, until Coulombic repulsion causes the droplet to
explode into smaller droplets. The process repeats itself until naked analytes are accomplished.
The only problem with this technique lies in the statistical probability that analytes will be
multiply-charged, which is not always desired. Smaller capillaries and slower flow rates
decrease this probability, and, therefore, increase m/z ratios.
Matrix-assisted laser desorption/ionization (MALDI) couples a LASER pulse with a
suitable matrix-embedded sample to produce molecular ions. The sample is embedded
homogeneously in the matrix on a metal probe, facilitated by co-crystalization. The matrix, a
small organic molecule, absorbs strongly at the wavelength of the LASER, and must itself be
sublimable. It serves to donate its excitation energy to the sample, protects the sample
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decomposition and/or aggregation of the analyte, and is also thought to donate protons to ionize
the analyte (Figure 86).

Figure 86: Illustration of a sample embedded in matrix on a metal probe.

This disadvantage of this technique is that the short duration of the ion burst produced by
the laser desorption prevents association of the source with quadropole analyzers, but makes it
ideal for coupling with time of flight (TOF) analysis.
The mass analyzer is the component that separates the molecular ions. This can be
accomplished based on the differential physical properties of the ions, done so in several ways.
In a double focusing sector mass analyzer, ions are accelerated through a potential into an
electrostatic analyzer, which focuses ions of the same m/z to the same path, improving
resolution. The ions then enter the magnetic sector, which produces a curved magnetic field—
between 60 and 120°—whose strength can be varied to direct the flight path of different m/z ions
toward the detector.
A time of flight mass analyzer accelerates molecular ions through a potential, supplying
them with a characteristic kinetic energy (KE). The ions are them allowed to fly down a long
chamber, or flight tube, under vacuum toward the detector. The ions will fly at a velocity
characteristic of their KE, and that is a function of their molecular weight.
PE = eV = KE = ½ mv2

(2)

where PE = potential energy (Joules), V = voltage (volts), e = electron volts, m = mass (kg), and
v = velocity (m/s).
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A quadropole mass analyzer is composed of four parallel rods, with static direct current
(DC) through two, and alternating radio frequency (rF) applied to the other two. Ions are passed
through the quad, and only those with the correct m/z values necessary to traject their path
straight through the poles are detected, while all others deflected. The mathematics behind the
physical event are complex, and will not be discussed.
In fourier transform ion cyclotron resonance (FT-ICR)—often referred to as FT-MS—,
ions are first focused into a vacuum chamber. They then enter a cell housing a static magnetic
field (B field), which causes the charged moieties to rotate in a circular orbit perpendicular to the
field at a velocity characteristic of their m/z, and governed by the Lorentzian force.
F = zvB

(3)

where F = Lorentzian force.
An angular frequency (ω) is obtained because the ion is bent into the circular path.
ω = zB/2πm

(4)

Ions are detected when an Rf pulse is used to excite ions at the correct m/z into a larger orbit.
The passing charge frequency is detected by two detectors located on either side of the cell, and
a waveform is recorded. The waveform is computed back to the ion’s m/z.
The ion trap is a system of three electrodes in a chamber that use varying voltages and Rf
to trap ions in (Figure 87).

Figure 87: Diagram of the ion trap mass analyer.

The ring electrode produces a three-dimensional electric field which causes ions to stay within
the cell, with a trajectory dependent on their m/z.
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The field is then changed to destabilize the ions’ trajectories, so that the ions are ejected
from the trap—smallest m/z to largest.
The third component is the detector which receives and processes the m/z signal. The
detector transforms the electrical signal into a digital mass spectra, which is a plot of the ion
intensity verses the m/z value.
Briefly, some general phenomenon associated with mass spectra, include the
manifestation of isotopic peaks of a given ion. This is caused by the presence of multiple atomic
isotopes that exist within a molecule, such as a deuterium ion (D) instead of a hydrogen. In
peptides/proteins, frequent isotopes of hydrogen, nitrogen, carbon, and sulfur are usually seen.
In a peptide spectra

(<5000 Daltons (Da)), the result is a collection of peaks at the m/z, the first

peak being the most abundant monoisotopic peak, except at higher mass values, where the
probability of having to higher mass isotope atoms among the population of atoms increases. In
a protein peak, isotope peaks are not clearly defined, but overlap each other (Figure 88).

Figure 88: Illustration of a general peptide and protein mass spectrum, revealing the phenomenon of isotopic
peaks.

Either the monoisotopic peak m/z can be used for analysis, or an average of the isotopic peaks
can be used to characterize the molecular ion.
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In biological samples, another frequently observed phenomenon is evidence of dimers,
where two homogeneous or heterogeneous molecules are associated with each other and
manifested in the same m/z peak. In the case of a homogeneous dimer, the m/z peak would
appear at twice the normal mass [M+] of the protein. A molecular ion can also be doublycharged [M2+], which would result in an m/z peak at half the normal mass value (Figure 89).

Figure 89: Simplified illustration showing the existence of a dimer peak and a doubly-charged peak [M2+] in the
same spectra as the normal molecular ion [M+].

Applications of MS are numerous and exist in research, testing, and development practices of
many areas; including industry, pharmaceuticals, academia, government, forensics and more. It
is probably the most useful and widely-used technique, today. Advancements of instrumentation
design continue to shape its influence and applicability in the progression of science.

APPENDIX II:
MALDI-TOF MS and PSD
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MALDI-TOF MS uses a soft ionization technique coupled to a time of flight analyzer to
provide quick m/z analysis of broad mass ranges with high sensitivity (see Appendix I). This
method can detect picomolar (pm) quanities of analyte, and there is virtually no upper mass limit
of detection.
For this research, a Bruker Biflex III MALDI-TOF was used. The Bruker Biflex III uses
a nitrogen LASER source of 337.1 nm wavelength and 0.1 nm spectral bandwidth. The matrices
used with this laser are sinapinic acid for proteins and α-cyano-4-hydroxycinnamic acid (HCCA)
for peptides (Table 11).

α-cyano-4-

Other names

Use

HCCA, α-cyano

Peptides

3,5-Dimethoxy-4hydroxycinnamic
acid

Proteins

Structure

hydroxycinnamic
acid

sinapinic acid

Table 11: Matrices coupled with the nitrogen laser source for the Bruker Biflex III MALDI-TOF MS.

After desorption, ions are accelerated by a potential energy (PE) of 19 kV, which gives
them a kinetic energy (KE), (equation 1). Ions are then allowed to travel down the time of flight
tube at a velocity (v) that is characteristic of their mass (m).
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PE = eV = KE = ½ mv2

(5)

where V = volts, e = electron volts. Smaller mass particles will travel faster and arrive at the
detector first. Mass to charge (m/z) values are computed based on the particles time of flight
after acceleration (equation 2).
TOF = L × √(m/z)/2Ve

(6)

where L = length of flight tube.
The instrument can activate in either positive or negative ion mode. Positive ion mode
accelerates postively-charged ions toward the detector using a negative PE. Negative ion mode
uses a positive voltage to accelerate negative ions.
The Bruker Biflex III design offers a delayed extraction function in which desorped and
ionized particles are caught and focused by a set of focusing voltages/lenses (Figure 90). When
the ions are blasted off the metal probe, they receive a KE. Each ion may have a different initial
KE and starting position within the ionization chamber/source from which they may be
accelerated (Figure 91).

Figure 90: Diagram of the source (ionization chamber) and TOF tube of the Bruker Biflex III MALDI-TOF MS.
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Figure 91: Illustration of the different starting positions of molecular ions in the ionization chamber prior
to acceleration.

This will affect their time at which they will arrive at the detector and can cause
broadening of peaks/loss of resolution. The focusing lenses help to equilibrate and concentrate
the particles before they are accelerated by the 19 kV.
The Biflex III also offers a reflectron mode to further improve resolution and to allow
post source decay (PSD) analysis. At the end of the flight tube are a series of reflector voltages
which deflect oncoming particles back towards a detector at the other end of the tube, supplying
a longer flight path and improved separation of ions (Figure 92). Reflectron mode is normally
used for the analysis of peptides ( <5000 Da). Linear mode is normally used for proteins.

Figure 92: Diagram of the path of ions after reflection due to the reflector voltages in reflectron mode of the
MALDI-TOF.
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The reflectron feature also facilitates PSD, which can be used to devise structural
information. A higher LASER power is used to supply more internal energy to the matrix and
analyte. An ion gate (voltage) is used to select the molecular ion (m/z value) to be fragmented
for PSD analysis. PSD theory makes use of the characteristic fragmentation of metastable
molecular ions that occurs because of high internal energy and collisions that occur between the
analyte, matrix ions, and/or residual gas in the flight tube (Kaufmann 1993). The molecular ion
achieves its characteristic KE, and then fragments. The fragments will all have the same
velocity, but the KE will be divided among the fragments (equation 3).
KE = ½ m1v2 + ½ m2v2 + ½ m3v2 + etc.

(7)

The technique uses stepwise decreases in reflector voltages, collecting spectra at each voltage.
Each reflector voltage focuses and deflects ions within a small KE range. This is known as a KE
filter. High mass fragments are deflected first, and then increasingly lower mass fragments are
deflected at each voltage. All the spectra are then computed and calibrated into a final
fragmentation spectrum. Several properties such as LASER attenuation, focusing lens voltages,
and reflector voltages can be adjusted to provide optimal resolution when collecting a spectrum.
A PSD spectrum reveals broken pieces of a peptide that can be put back together like a
puzzle to reveal connectivity of composite amino acids. This can be used to devise structural
information because fragmentation occurs along the weakest bond. In protein samples, this is
usually the peptide bond (Figure 93).

Figure 93: Illustration of the fragmentation of a peptide bond during PSD analysis.
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Some limitations of PSD are that it is time-consuming to collect a spectrum at each
reflector voltage, and then paste the spectra together. The technique is also less sensitive
because it requires an increased amount of sample. A sample is depleted as a spectrum has to be
collected at each voltage. There is also a loss of resolution associated with PSD that the reflector
voltage normally supplies in normal analysis of peptides.
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Appendix III:
General Steps Involved in Proteomic Analysis of Biological Samples
1. Isolation of Proteins
Isolation is usually facilitated by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide
gel electrophoresis), in either one (1D) or two dimensions (2D). 1D electrophoresis separates a
solubilized mixture of proteins by their molecular weight (MW), only. 2D electrophoresis also
separates protein fractions by their isoelectric point (pI) in a pH gradient strip or gel. Isolation
can also be accomplished by chromatography, in which various affinity reactions selectively
retain desired products through antibody binding, enzyme-substrate association, or other specific
chemical reactions (phosphorylation, glucosylation). A less efficient separation can be
accomplished by centrifugation.
2. Purification
Purification of samples can be achieved by dialysis prior to or after electrophoresis to
filter lower MW contaminates such as salts from buffers or detergents, etc through a porous
membrane in solution. Reverse-phase HPLC (high pressure liquid chromatography) or Ziptip
concentration and desalting may be applied to protein/peptide mixtures, as well. In these
methods, proteins or peptides mixtures are passed through and retained by tightly-packed
columns of hydrophobic resin. They are then eluted off the column with a hydrophobic solvent,
such as acetonitrile.
3. Analysis
Analysis is usually performed using some form of mass spectrometry (MS), (see
appendix I). Information that can be obtained by MS includes 1) MW, 2) amino acid (aa)
sequence of peptides/proteins, 3) detection of post-translational modifications (phosphorylation
sites, glucosylation sites), 4) detection of mutations, 5) isotopic abundance, 6) fragmentation
patterns revealing structural information, 7) peptide fingerprints of proteolytically digested
proteins, and 8) identification of unknown proteins when coupled with peptide maps in protein
databases (facilitated to a large degree by the HGP).
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APPENDIX IV:
Important Proteins in Smooth Muscle
Protein

MW (Da)

Theor-

Function

etical pI
α-Actin

41,747

5.24

Known PSites

Composition of thin

UNKNOWN

filaments.
Myosin Heavy

79,985

Undefined Fragment of MHC that

UNKNOWN

makes up the thick filaments.

Chain (MHC)–
SM1A fragment
MHC—SM1B

80,736

Undefined Fragment of MHC that make

UNKNOWN

up the thick filaments.

fragment
16,843.9

4.46

Part of the myosin head.

UNKNOWN

19,764.1

4.67

Part of the myosin head.

Thr-18

light chain (MLC-

Regulates activity of

Ser-19

20)

actomyosin motor.

Myosin essential
light chain
(MLCessential)
Myosin regulatory

Heavy

------------

meromyosin

------------

Fragment of myosin formed

-------

by trypsin digestion—hinge
region and ATPase.

(HMM)
Light meromyosin
(LMM)

UNKNOWN

------------

------------

-

-------

Fragment of myosin formed

UNKNOWN

during trypsin digestion—
associates w/ other LMM to
form filament.

Tropomyosin (Tm)

32,957.7

4.63

Thin-filament-associated

UNKNOWN

protein-may help regulate
contraction.
Myosin light chain
kinase (MLCK)

113,993

5.48

Induces contraction by

UNKNOWN

phosphorylating MLC-20.
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Myosin light chain

26,262

5.78

Inhibits contraction by

UNKNOWN

dephosphorylating MLC-20.

phophatase
(MLCP)—cardiac
isoform
MYPT1—MLCP

8812

Undefined Subunit of MLCP that targets UNKNOWN
myosin.

subunit
PP1C—MLCP

36,983

6.12

Catalytic subunit of MLCP

UNKNOWN

that dephosphorylates MLC-

subunit

20
20 kDa Fragment

~20, 000

Undefined Subunit of MLCP. Unknown UNKNOWN
function

Tropomyosin (Tm)

32,138.99

4.90

Associated with actin thin

UNKNOWN

filaments. May help regulate
contraction.
Calmodulin (CaM)

16,706.3

4.09

Binds Ca2+ after influx;

Thr-44

combines with MLCK to
activate it.
α-Actinin

103,653.5

5.36

Found in the dense bodies of

UNKNOWN

SM, analogous to z-discs in
skeletal muscle—serve as
attachments points for actin
filaments.
Desmin

53,366.6

5.21

Found in the intermediate

UNKNOWN

filaments of SM.
Vimentin
Smoothelin

53,524.0
100,135

5.06
9.01

Found in the intermediate

Ser-38

filaments of SM.

Ser-82

Filamentous structural

UNKNOWN

calponin-like protein present
in the cytoplasm.
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Calreticulin

46,319.8

4.33

Binds Ca2+ in the SR.

UNKNOWN

Calsequestrin

41,662.9

3.96

Binds Ca2+ in the SR.

UNKNOWN

SR membrane protein that

Ser-16

may regulate the Ca2+ pump

Thr-17

Phospholamban

in the SR when
phosphorylated.
RhoA

21,428.8

5.83

Regulatory protein in

UNKNOWN

pathway of agonist-induced
contraction.
Rho-associated

159.526.6

5.72

Regulatory protein activated

UNKNOWN

by RhoA. (See Appendix

Kinase (ROK)

IIIf)
Regulatory kinase activated

Ser-10

protein kinase

by elevated [cAMP]. (See

Ser-139

(PKA)

Appendix IIIe)

Ser-338

cAMP-dependent

40,462.9

8.71

Thr-197
Lys-72 (ATP)
cGMP-dependent

Undefined

Undefined Same as PKA.

UNKNOWN

protein kinase
(PKG)
Protein Kinase C

76,742.9

6.61

(PKC)

Regulatory kinase activated

Thr-638

by IP3. (See Appendix IIId)

Thr-631
Lys-368 (ATP)

Phospholipase C-β

138,257.5

5.86

Ser-887

IP3 and DAG.

(PLC-β)
ZIP kinase

Cleaves phosphinositol into

51,3891.8

8.91

Phosphorylates MLCP and

UNKNOWN

CPI-17. May be activated by
ROK.
Calmodulin kinase
II (CaM KII)

60,042.6

6.84

Regulatory kinase activated

Lys-42 (ATP)

by elevated [Ca2+]. (See
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Appendices IIIa and IIIb)
Integrin-linked

51313.9

8.30

Regulatory kinase that

Lys-220 (ATP)

phosphorylates MLC-20.

kinase

Regulatory kinase in

Thr-180

protein kinase

contraction. (See Appendix

Tyr-182

(MAPK)

IIIg)

Lys-54 (ATP)

Phosphorylates and activates

Ser-217

MAPK.

Ser-221

Mitogen-activated

Mitogen-activated

42,023.8

43,306.3

8.67

6.20

protein kinase

Lys-96 (ATP)

kinase (MAPKK)
Raf

67,508.37

9.27

Regulatory kinase involved

Lys-334 (ATP)

in contraction. (See
Appendix IIIg)
Ras

21,300.58

5.16

Regulatory GTPAse protein

UNKNOWN

involved in contraction. (See
Appendix IIIg)
Phospholipase A2

13665.9

4.88

Calcium-dependent enzyme

UNKNOWN

that cleaves arachidonic acid

(PLA2)

(AA) from phospholipids.
Heat shock protein

17.494.1

6.05

Inactivates the actomyosin

UNKNOWN

MgATPase when

20 (HSP-20)

phosphorylated by
PKA/PKG
Ryanodine

Ca2+ ion channel in the SR.

receptor (RyaR)

Allows Ca2+ influx. (See

UNKNOWN

Appendix IIIc)
IP3 receptor Ca2+

Undefined

Undefined Ca2+ ion channel in the SR.

UNKNOWN

Allows Ca2+ influx. (See

channel

Appendix IIIc)
Ca2+/Na+
Exchanger

Undefined

Undefined

Ca2+ ion channel in the

UNKNOWN

plasma membrane (PM).
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Removes Ca2+ from the
cytosol. (See Appendix IIIc)
Ca2+-ATPase

Undefined

pump

Undefined Ca2+ ion channel in the PM.

UNKNOWN

Removes Ca2+ from the
cytosol. (See Appendix IIIc)

P-Sites = Phosphorylation Sites
Information was obtained from the Swiss-Prot protein database.237
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APPENDIX V:
20 Common Amino Acids
Name

Abbrev.

Symbol

MW

pI

1. Alanine

Ala

A

89.09

6.00

2. Arginine

Arg

R

174.2

11.15

3. Asparagine

Asn

N

132.12

5.41

4. Aspartic Acid

Asp

D

133.10

2.77

5. Cysteine

Cys

C

121.15

5.02

6. Glutamine

Gln

Q

146.15

5.65

Structure
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7. Glutamic Acid

Glu

E

147.13

3.22

8. Glycine

Gly

G

75.07

5.97

9. Histidine

His

H

155.16

7.47

10. Isoleucine

Ile

I

131.17

5.94

11. Leucine

Leu

L

131.17

5.98

12. Lysine

Lys

K

146.19

9.59

13. Methionine

Met

M

149.21

5.71

F

165.19

5.41

14. Phenylalanine Phe
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15. Proline

Pro

P

115.13

6.30

16. Serine

Ser

S

105.09

5.68

17. Threonine

Thr

T

119.12

5.64

18. Tryptophan

Trp

W

204.23

5.89

19. Tyrosine

Tyr

Y

181.19

5.66

20. Valine

Val

V

117.15

5.96
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